{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T10:51:51Z","timestamp":1794135111756,"version":"4.8.0"},"reference-count":548,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82102850"],"award-info":[{"award-number":["82102850"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82003223"],"award-info":[{"award-number":["82003223"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010031","name":"Postdoctoral Research Foundation of China","doi-asserted-by":"publisher","award":["2020M671399"],"award-info":[{"award-number":["2020M671399"]}],"id":[{"id":"10.13039\/501100010031","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"DOI":"10.1038\/s41392-026-02682-9","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T23:03:17Z","timestamp":1786402997000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["C-MET tyrosine kinase receptor: mechanisms, clinical applications and future perspectives in cancer therapy"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8798-6367","authenticated-orcid":false,"given":"Chenjing","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanzi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuancheng","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengxian","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingjuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,11]]},"reference":[{"key":"2682_CR1","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel, R. L., Giaquinto, A. N. & Jemal, A. Cancer statistics, 2024. CA Cancer J. Clin. 74, 12\u201349 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"2682_CR2","first-page":"10","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel, R. L. et al. Cancer statistics, 2025. CA Cancer J. Clin. 75, 10\u201345 (2025).","journal-title":"CA Cancer J. Clin."},{"key":"2682_CR3","doi-asserted-by":"publisher","first-page":"116477","DOI":"10.1016\/j.ejmech.2024.116477","volume":"272","author":"F Jin","year":"2024","unstructured":"Jin, F. et al. Recent advances in c-Met-based dual inhibitors in the treatment of cancers. Eur. J. Med. Chem. 272, 116477 (2024).","journal-title":"Eur. J. Med. Chem."},{"key":"2682_CR4","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.ejphar.2018.07.034","volume":"834","author":"YT Lee","year":"2018","unstructured":"Lee, Y. T., Tan, Y. J. & Oon, C. E. Molecular targeted therapy: treating cancer with specificity. Eur. J. Pharm. 834, 188\u2013196 (2018).","journal-title":"Eur. J. Pharm."},{"key":"2682_CR5","doi-asserted-by":"publisher","first-page":"21","DOI":"10.21037\/cco.2017.04.04","volume":"6","author":"AA Mokdad","year":"2017","unstructured":"Mokdad, A. A., Hester, C. A., Singal, A. G. & Yopp, A. C. Management of hepatocellular in the United States. Chin. Clin. Oncol. 6, 21 (2017).","journal-title":"Chin. Clin. Oncol."},{"key":"2682_CR6","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1200\/JCO.2007.13.9949","volume":"26","author":"S Johnston","year":"2008","unstructured":"Johnston, S. et al. Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy. J. Clin. Oncol. 26, 1066\u20131072 (2008).","journal-title":"J. Clin. Oncol."},{"key":"2682_CR7","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.critrevonc.2018.11.009","volume":"133","author":"L Belgioia","year":"2019","unstructured":"Belgioia, L. et al. Safety and efficacy of combined radiotherapy, immunotherapy and targeted agents in elderly patients: a literature review. Crit. Rev. Oncol. Hematol. 133, 163\u2013170 (2019).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"2682_CR8","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1200\/JCO.2006.06.3602","volume":"25","author":"LQ Chow","year":"2007","unstructured":"Chow, L. Q. & Eckhardt, S. G. Sunitinib: from rational design to clinical efficacy. J. Clin. Oncol. 25, 884\u2013896 (2007).","journal-title":"J. Clin. Oncol."},{"key":"2682_CR9","doi-asserted-by":"publisher","first-page":"4477","DOI":"10.1073\/pnas.0306068101","volume":"101","author":"CG Huh","year":"2004","unstructured":"Huh, C. G. et al. Hepatocyte growth factor\/c-met signaling pathway is required for efficient liver regeneration and repair. Proc. Natl. Acad. Sci. USA 101, 4477\u20134482 (2004).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2682_CR10","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1038\/376768a0","volume":"376","author":"F Bladt","year":"1995","unstructured":"Bladt, F. et al. Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud. Nature 376, 768\u2013771 (1995).","journal-title":"Nature"},{"key":"2682_CR11","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1038\/373702a0","volume":"373","author":"Y Uehara","year":"1995","unstructured":"Uehara, Y. et al. Placental defect and embryonic lethality in mice lacking hepatocyte growth factor\/scatter factor. Nature 373, 702\u2013705 (1995).","journal-title":"Nature"},{"key":"2682_CR12","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/373699a0","volume":"373","author":"C Schmidt","year":"1995","unstructured":"Schmidt, C. et al. Scatter factor\/hepatocyte growth factor is essential for liver development. Nature 373, 699\u2013702 (1995).","journal-title":"Nature"},{"key":"2682_CR13","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1038\/onc.2010.532","volume":"30","author":"AK Mitra","year":"2011","unstructured":"Mitra, A. K. et al. Ligand-independent activation of c-Met by fibronectin and alpha(5)beta(1)-integrin regulates ovarian cancer invasion and metastasis. Oncogene 30, 1566\u20131576 (2011).","journal-title":"Oncogene"},{"key":"2682_CR14","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1016\/j.jtho.2019.06.023","volume":"14","author":"T Fujino","year":"2019","unstructured":"Fujino, T. et al. Sensitivity and resistance of MET exon 14 mutations in lung cancer to eight MET tyrosine kinase inhibitors in vitro. J. Thorac. Oncol. 14, 1753\u20131765 (2019).","journal-title":"J. Thorac. Oncol."},{"key":"2682_CR15","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1158\/1078-0432.CCR-22-2540","volume":"29","author":"EC Chen","year":"2023","unstructured":"Chen, E. C. et al. Targeting MET and FGFR in relapsed or refractory acute myeloid leukemia: preclinical and clinical findings, and signal transduction correlates. Clin. Cancer Res. 29, 878\u2013887 (2023).","journal-title":"Clin. Cancer Res."},{"key":"2682_CR16","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1007\/s40265-020-01347-3","volume":"80","author":"S Dhillon","year":"2020","unstructured":"Dhillon, S. Capmatinib: first approval. Drugs 80, 1125\u20131131 (2020).","journal-title":"Drugs"},{"key":"2682_CR17","doi-asserted-by":"publisher","first-page":"4203","DOI":"10.1002\/cncr.34493","volume":"128","author":"MS Brose","year":"2022","unstructured":"Brose, M. S. et al. Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: updated results from the phase 3 COSMIC-311 trial. Cancer 128, 4203\u20134212 (2022).","journal-title":"Cancer"},{"key":"2682_CR18","first-page":"3314","volume":"49","author":"R Zarnegar","year":"1989","unstructured":"Zarnegar, R. & Michalopoulos, G. Purification and biological characterization of human hepatopoietin A, a polypeptide growth factor for hepatocytes. Cancer Res. 49, 3314\u20133320 (1989).","journal-title":"Cancer Res."},{"key":"2682_CR19","first-page":"2545","volume":"45","author":"FJ Thaler","year":"1985","unstructured":"Thaler, F. J. & Michalopoulos, G. K. Hepatopoietin A: partial characterization and trypsin activation of a hepatocyte growth factor. Cancer Res. 45, 2545\u20132549 (1985).","journal-title":"Cancer Res."},{"key":"2682_CR20","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/342440a0","volume":"342","author":"T Nakamura","year":"1989","unstructured":"Nakamura, T. et al. Molecular cloning and expression of human hepatocyte growth factor. Nature 342, 440\u2013443 (1989).","journal-title":"Nature"},{"key":"2682_CR21","doi-asserted-by":"publisher","first-page":"2976","DOI":"10.1523\/JNEUROSCI.2278-19.2020","volume":"40","author":"RJ Morell","year":"2020","unstructured":"Morell, R. J. et al. Noncoding microdeletion in mouse hgf disrupts neural crest migration into the stria vascularis, reduces the endocochlear potential, and suggests the neuropathology for human nonsyndromic deafness DFNB39. J. Neurosci. 40, 2976\u20132992 (2020).","journal-title":"J. Neurosci."},{"key":"2682_CR22","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1073\/pnas.88.2.415","volume":"88","author":"JS Rubin","year":"1991","unstructured":"Rubin, J. S. et al. A broad-spectrum human lung fibroblast-derived mitogen is a variant of hepatocyte growth factor. Proc. Natl. Acad. Sci. USA 88, 415\u2013419 (1991).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2682_CR23","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1046\/j.1523-1747.1998.00418.x","volume":"111","author":"J Gille","year":"1998","unstructured":"Gille, J., Khalik, M., Konig, V. & Kaufmann, R. Hepatocyte growth factor\/scatter factor (HGF\/SF) induces vascular permeability factor (VPF\/VEGF) expression by cultured keratinocytes. J. Invest. Dermatol. 111, 1160\u20131165 (1998).","journal-title":"J. Invest. Dermatol."},{"key":"2682_CR24","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1083\/jcb.111.5.2097","volume":"111","author":"KM Weidner","year":"1990","unstructured":"Weidner, K. M., Behrens, J., Vandekerckhove, J. & Birchmeier, W. Scatter factor: molecular characteristics and effect on the invasiveness of epithelial cells. J. Cell Biol. 111, 2097\u20132108 (1990).","journal-title":"J. Cell Biol."},{"key":"2682_CR25","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ajhg.2009.06.003","volume":"85","author":"JM Schultz","year":"2009","unstructured":"Schultz, J. M. et al. Noncoding mutations of HGF are associated with nonsyndromic hearing loss, DFNB39. Am. J. Hum. Genet 85, 25\u201339 (2009).","journal-title":"Am. J. Hum. Genet"},{"key":"2682_CR26","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/j.jtho.2016.05.005","volume":"11","author":"N Van Der Steen","year":"2016","unstructured":"Van Der Steen, N. et al. cMET exon 14 skipping: from the structure to the clinic. J. Thorac. Oncol. 11, 1423\u20131432 (2016).","journal-title":"J. Thorac. Oncol."},{"key":"2682_CR27","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/327239a0","volume":"327","author":"M Stoker","year":"1987","unstructured":"Stoker, M., Gherardi, E., Perryman, M. & Gray, J. Scatter factor is a fibroblast-derived modulator of epithelial cell mobility. Nature 327, 239\u2013242 (1987).","journal-title":"Nature"},{"key":"2682_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-018-0202-2","volume":"51","author":"HK Byeon","year":"2019","unstructured":"Byeon, H. K., Ku, M. & Yang, J. Beyond EGFR inhibition: multilateral combat strategies to stop the progression of head and neck cancer. Exp. Mol. Med. 51, 1\u201314 (2019).","journal-title":"Exp. Mol. Med."},{"key":"2682_CR29","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1002\/j.1460-2075.1992.tb05315.x","volume":"11","author":"NA Lokker","year":"1992","unstructured":"Lokker, N. A. et al. Structure-function analysis of hepatocyte growth factor: identification of variants that lack mitogenic activity yet retain high affinity receptor binding. EMBO J. 11, 2503\u20132510 (1992).","journal-title":"EMBO J."},{"key":"2682_CR30","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.jmb.2006.12.061","volume":"367","author":"O Holmes","year":"2007","unstructured":"Holmes, O. et al. Insights into the structure\/function of hepatocyte growth factor\/scatter factor from studies with individual domains. J. Mol. Biol. 367, 395\u2013408 (2007).","journal-title":"J. Mol. Biol."},{"key":"2682_CR31","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1126\/science.1846706","volume":"251","author":"DP Bottaro","year":"1991","unstructured":"Bottaro, D. P. et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 251, 802\u2013804 (1991).","journal-title":"Science"},{"key":"2682_CR32","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/311029a0","volume":"311","author":"CS Cooper","year":"1984","unstructured":"Cooper, C. S. et al. Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature 311, 29\u201333 (1984).","journal-title":"Nature"},{"key":"2682_CR33","doi-asserted-by":"publisher","first-page":"6379","DOI":"10.1073\/pnas.84.18.6379","volume":"84","author":"M Park","year":"1987","unstructured":"Park, M. et al. Sequence of MET protooncogene cDNA has features characteristic of the tyrosine kinase family of growth-factor receptors. Proc. Natl. Acad. Sci. USA 84, 6379\u20136383 (1987).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2682_CR34","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/318385a0","volume":"318","author":"M Dean","year":"1985","unstructured":"Dean, M. et al. The human met oncogene is related to the tyrosine kinase oncogenes. Nature 318, 385\u2013388 (1985).","journal-title":"Nature"},{"key":"2682_CR35","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/0014-5793(93)80958-W","volume":"328","author":"M Komada","year":"1993","unstructured":"Komada, M. et al. Proteolytic processing of the hepatocyte growth factor\/scatter factor receptor by furin. FEBS Lett. 328, 25\u201329 (1993).","journal-title":"FEBS Lett."},{"key":"2682_CR36","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1177\/1758834011422556","volume":"3","author":"SL Organ","year":"2011","unstructured":"Organ, S. L. & Tsao, M. S. An overview of the c-MET signaling pathway. Ther. Adv. Med. Oncol. 3, S7\u2013S19 (2011).","journal-title":"Ther. Adv. Med. Oncol."},{"key":"2682_CR37","doi-asserted-by":"publisher","first-page":"12039","DOI":"10.1073\/pnas.2034936100","volume":"100","author":"E Gherardi","year":"2003","unstructured":"Gherardi, E. et al. Functional map and domain structure of MET, the product of the c-met protooncogene and receptor for hepatocyte growth factor\/scatter factor. Proc. Natl. Acad. Sci. USA 100, 12039\u201312044 (2003).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2682_CR38","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/S1097-2765(01)00378-1","volume":"8","author":"P Peschard","year":"2001","unstructured":"Peschard, P. et al. Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein. Mol. Cell 8, 995\u20131004 (2001).","journal-title":"Mol. Cell"},{"key":"2682_CR39","first-page":"2019","volume":"9","author":"GA Rodrigues","year":"1994","unstructured":"Rodrigues, G. A. & Park, M. Autophosphorylation modulates the kinase activity and oncogenic potential of the Met receptor tyrosine kinase. Oncogene 9, 2019\u20132027 (1994).","journal-title":"Oncogene"},{"key":"2682_CR40","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1080\/10408363.2019.1653821","volume":"56","author":"F Moosavi","year":"2019","unstructured":"Moosavi, F., Giovannetti, E., Saso, L. & Firuzi, O. HGF\/MET pathway aberrations as diagnostic, prognostic, and predictive biomarkers in human cancers. Crit. Rev. Clin. Lab Sci. 56, 533\u2013566 (2019).","journal-title":"Crit. Rev. Clin. Lab Sci."},{"key":"2682_CR41","doi-asserted-by":"publisher","first-page":"4625","DOI":"10.1038\/s41388-021-01863-w","volume":"40","author":"J Fu","year":"2021","unstructured":"Fu, J. et al. HGF\/c-MET pathway in cancer: from molecular characterization to clinical evidence. Oncogene 40, 4625\u20134651 (2021).","journal-title":"Oncogene"},{"key":"2682_CR42","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/nrm3941","volume":"16","author":"S Venkatesh","year":"2015","unstructured":"Venkatesh, S. & Workman, J. L. Histone exchange, chromatin structure and the regulation of transcription. Nat. Rev. Mol. Cell Biol. 16, 178\u2013189 (2015).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2682_CR43","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1093\/carcin\/bgw015","volume":"37","author":"J Zhang","year":"2016","unstructured":"Zhang, J. & Babic, A. Regulation of the MET oncogene: molecular mechanisms. Carcinogenesis 37, 345\u2013355 (2016).","journal-title":"Carcinogenesis"},{"key":"2682_CR44","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/nrm4043","volume":"16","author":"J Du","year":"2015","unstructured":"Du, J., Johnson, L. M., Jacobsen, S. E. & Patel, D. J. DNA methylation pathways and their crosstalk with histone methylation. Nat. Rev. Mol. Cell Biol. 16, 519\u2013532 (2015).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2682_CR45","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1002\/ijc.28765","volume":"135","author":"K Nones","year":"2014","unstructured":"Nones, K. et al. Genome-wide DNA methylation patterns in pancreatic ductal adenocarcinoma reveal epigenetic deregulation of SLIT-ROBO, ITGA2 and MET signaling. Int. J. Cancer 135, 1110\u20131118 (2014).","journal-title":"Int. J. Cancer"},{"key":"2682_CR46","doi-asserted-by":"publisher","first-page":"a018762","DOI":"10.1101\/cshperspect.a018762","volume":"6","author":"R Marmorstein","year":"2014","unstructured":"Marmorstein, R. & Zhou, M. M. Writers and readers of histone acetylation: structure, mechanism, and inhibition. Cold Spring Harb. Perspect. Biol. 6, a018762 (2014).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"2682_CR47","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/339155a0","volume":"339","author":"S Giordano","year":"1989","unstructured":"Giordano, S. et al. Tyrosine kinase receptor indistinguishable from the c-met protein. Nature 339, 155\u2013156 (1989).","journal-title":"Nature"},{"key":"2682_CR48","doi-asserted-by":"publisher","first-page":"12852","DOI":"10.1016\/S0021-9258(18)99954-0","volume":"269","author":"G Gambarotta","year":"1994","unstructured":"Gambarotta, G. et al. Structure and inducible regulation of the human MET promoter. J. Biol. Chem. 269, 12852\u201312857 (1994).","journal-title":"J. Biol. Chem."},{"key":"2682_CR49","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1038\/aps.2009.84","volume":"30","author":"J Qian","year":"2009","unstructured":"Qian, J. et al. alpha2,6-hyposialylation of c-Met abolishes cell motility of ST6Gal-I-knockdown HCT116 cells. Acta Pharm. Sin. 30, 1039\u20131045 (2009).","journal-title":"Acta Pharm. Sin."},{"key":"2682_CR50","doi-asserted-by":"publisher","first-page":"5580","DOI":"10.1158\/0008-5472.CAN-13-0869","volume":"73","author":"YM Wu","year":"2013","unstructured":"Wu, Y. M. et al. C1GALT1 enhances proliferation of hepatocellular carcinoma cells via modulating MET glycosylation and dimerization. Cancer Res. 73, 5580\u20135590 (2013).","journal-title":"Cancer Res."},{"key":"2682_CR51","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1002\/hep.26738","volume":"59","author":"CK Chen","year":"2014","unstructured":"Chen, C. K. et al. Leukocyte cell-derived chemotaxin 2 antagonizes MET receptor activation to suppress hepatocellular carcinoma vascular invasion by protein tyrosine phosphatase 1B recruitment. Hepatology 59, 974\u2013985 (2014).","journal-title":"Hepatology"},{"key":"2682_CR52","first-page":"1383","volume":"4","author":"S Giordano","year":"1989","unstructured":"Giordano, S. et al. Biosynthesis of the protein encoded by the c-met proto-oncogene. Oncogene 4, 1383\u20131388 (1989).","journal-title":"Oncogene"},{"key":"2682_CR53","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s00401-015-1420-5","volume":"130","author":"AC Navis","year":"2015","unstructured":"Navis, A. C. et al. Identification of a novel MET mutation in high-grade glioma resulting in an auto-active intracellular protein. Acta Neuropathol. 130, 131\u2013144 (2015).","journal-title":"Acta Neuropathol."},{"key":"2682_CR54","doi-asserted-by":"publisher","first-page":"4612","DOI":"10.1158\/1078-0432.CCR-08-0108","volume":"14","author":"Z Tiran","year":"2008","unstructured":"Tiran, Z. et al. A novel recombinant soluble splice variant of Met is a potent antagonist of the hepatocyte growth factor\/scatter factor-Met pathway. Clin. Cancer Res. 14, 4612\u20134621 (2008).","journal-title":"Clin. Cancer Res."},{"key":"2682_CR55","first-page":"49","volume":"9","author":"P Longati","year":"1994","unstructured":"Longati, P. et al. Tyrosines1234-1235 are critical for activation of the tyrosine kinase encoded by the MET proto-oncogene (HGF receptor). Oncogene 9, 49\u201357 (1994).","journal-title":"Oncogene"},{"key":"2682_CR56","doi-asserted-by":"publisher","first-page":"L56","DOI":"10.1152\/ajplung.00417.2012","volume":"305","author":"Y Zhao","year":"2013","unstructured":"Zhao, Y. et al. Lipopolysaccharide-induced phosphorylation of c-Met tyrosine residue 1003 regulates c-Met intracellular trafficking and lung epithelial barrier function. Am. J. Physiol. Lung Cell Mol. Physiol. 305, L56\u2013L63 (2013).","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"2682_CR57","doi-asserted-by":"publisher","first-page":"28970","DOI":"10.1074\/jbc.M402508200","volume":"279","author":"OM Fischer","year":"2004","unstructured":"Fischer, O. M., Giordano, S., Comoglio, P. M. & Ullrich, A. Reactive oxygen species mediate Met receptor transactivation by G protein-coupled receptors and the epidermal growth factor receptor in human carcinoma cells. J. Biol. Chem. 279, 28970\u201328978 (2004).","journal-title":"J. Biol. Chem."},{"key":"2682_CR58","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1158\/2159-8290.CD-15-0285","volume":"5","author":"GM Frampton","year":"2015","unstructured":"Frampton, G. M. et al. Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. Cancer Discov. 5, 850\u2013859 (2015).","journal-title":"Cancer Discov."},{"key":"2682_CR59","doi-asserted-by":"publisher","first-page":"11445","DOI":"10.1073\/pnas.94.21.11445","volume":"94","author":"M Jeffers","year":"1997","unstructured":"Jeffers, M. et al. Activating mutations for the met tyrosine kinase receptor in human cancer. Proc. Natl. Acad. Sci. USA 94, 11445\u201311450 (1997).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2682_CR60","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1200\/JCO.2015.62.0674","volume":"34","author":"X Liu","year":"2016","unstructured":"Liu, X. et al. Next-generation sequencing of pulmonary sarcomatoid carcinoma reveals high frequency of actionable MET gene mutations. J. Clin. Oncol. 34, 794\u2013802 (2016).","journal-title":"J. Clin. Oncol."},{"key":"2682_CR61","doi-asserted-by":"publisher","first-page":"13110","DOI":"10.1074\/jbc.271.22.13110","volume":"271","author":"V Cioce","year":"1996","unstructured":"Cioce, V. et al. Hepatocyte growth factor (HGF)\/NK1 is a naturally occurring HGF\/scatter factor variant with partial agonist\/antagonist activity. J. Biol. Chem. 271, 13110\u201313115 (1996).","journal-title":"J. Biol. Chem."},{"key":"2682_CR62","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S0960-9822(98)70059-4","volume":"8","author":"G Hartmann","year":"1998","unstructured":"Hartmann, G. et al. Engineered mutants of HGF\/SF with reduced binding to heparan sulphate proteoglycans, decreased clearance and enhanced activity in vivo. Curr. Biol. 8, 125\u2013134 (1998).","journal-title":"Curr. Biol."},{"key":"2682_CR63","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24367-3","volume":"12","author":"E Uchikawa","year":"2021","unstructured":"Uchikawa, E. et al. Structural basis of the activation of c-MET receptor. Nat. Commun. 12, 4074 (2021).","journal-title":"Nat. Commun."},{"key":"2682_CR64","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.canlet.2017.11.034","volume":"415","author":"MS Huang","year":"2018","unstructured":"Huang, M. S. et al. LncRNAs and CircRNAs from the same gene: masterpieces of RNA splicing. Cancer Lett. 415, 49\u201357 (2018).","journal-title":"Cancer Lett."},{"key":"2682_CR65","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-1069-0","volume":"18","author":"C Shan","year":"2019","unstructured":"Shan, C. et al. Biogenesis, functions and clinical significance of circRNAs in gastric cancer. Mol. Cancer 18, 136 (2019).","journal-title":"Mol. Cancer"},{"key":"2682_CR66","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/nrm.2015.32","volume":"17","author":"LL Chen","year":"2016","unstructured":"Chen, L. L. The biogenesis and emerging roles of circular RNAs. Nat. Rev. Mol. Cell Biol. 17, 205\u2013211 (2016).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2682_CR67","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s13046-023-02690-5","volume":"42","author":"F Bersani","year":"2023","unstructured":"Bersani, F. et al. Exploring circular MET RNA as a potential biomarker in tumors exhibiting high MET activity. J. Exp. Clin. Cancer Res. 42, 120 (2023).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2682_CR68","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.molcel.2013.08.017","volume":"51","author":"Y Zhang","year":"2013","unstructured":"Zhang, Y. et al. Circular intronic long noncoding RNAs. Mol. Cell 51, 792\u2013806 (2013).","journal-title":"Mol. Cell"},{"key":"2682_CR69","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1261\/rna.045781.114","volume":"20","author":"GJ Talhouarne","year":"2014","unstructured":"Talhouarne, G. J. & Gall, J. G. Lariat intronic RNAs in the cytoplasm of Xenopus tropicalis oocytes. RNA 20, 1476\u20131487 (2014).","journal-title":"RNA"},{"key":"2682_CR70","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1186\/s13046-020-01799-1","volume":"39","author":"H Xu","year":"2020","unstructured":"Xu, H. et al. CircRNA_0000392 promotes colorectal cancer progression through the miR-193a-5p\/PIK3R3\/AKT axis. J. Exp. Clin. Cancer Res. 39, 283 (2020).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2682_CR71","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.7150\/thno.45302","volume":"11","author":"L Wang","year":"2021","unstructured":"Wang, L. et al. Estrogen-induced circRNA, circPGR, functions as a ceRNA to promote estrogen receptor-positive breast cancer cell growth by regulating cell cycle-related genes. Theranostics 11, 1732\u20131752 (2021).","journal-title":"Theranostics"},{"key":"2682_CR72","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-021-02903-5","volume":"19","author":"Z Dong","year":"2021","unstructured":"Dong, Z. et al. Identification of circRNA-miRNA-mRNA networks contributes to explore underlying pathogenesis and therapy strategy of gastric cancer. J. Transl. Med. 19, 226 (2021).","journal-title":"J. Transl. Med."},{"key":"2682_CR73","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.canlet.2021.02.004","volume":"505","author":"L Chen","year":"2021","unstructured":"Chen, L. & Shan, G. CircRNA in cancer: fundamental mechanism and clinical potential. Cancer Lett. 505, 49\u201357 (2021).","journal-title":"Cancer Lett."},{"key":"2682_CR74","doi-asserted-by":"publisher","first-page":"2839","DOI":"10.1158\/0008-5472.CAN-17-2808","volume":"78","author":"M Qiu","year":"2018","unstructured":"Qiu, M. et al. The circular RNA circPRKCI promotes tumor growth in lung adenocarcinoma. Cancer Res. 78, 2839\u20132851 (2018).","journal-title":"Cancer Res."},{"key":"2682_CR75","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/onc.2017.361","volume":"37","author":"LS Kristensen","year":"2018","unstructured":"Kristensen, L. S., Hansen, T. B., Veno, M. T. & Kjems, J. Circular RNAs in cancer: opportunities and challenges in the field. Oncogene 37, 555\u2013565 (2018).","journal-title":"Oncogene"},{"key":"2682_CR76","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01497-w","volume":"21","author":"L Yang","year":"2022","unstructured":"Yang, L. et al. CircMET promotes tumor proliferation by enhancing CDKN2A mRNA decay and upregulating SMAD3. Mol. Cancer 21, 23 (2022).","journal-title":"Mol. Cancer"},{"key":"2682_CR77","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-01213-6","volume":"19","author":"XY Huang","year":"2020","unstructured":"Huang, X. Y. et al. Circular RNA circMET drives immunosuppression and anti-PD1 therapy resistance in hepatocellular carcinoma via the miR-30-5p\/snail\/DPP4 axis. Mol. Cancer 19, 92 (2020).","journal-title":"Mol. Cancer"},{"key":"2682_CR78","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-01224-3","volume":"19","author":"L Zhang","year":"2020","unstructured":"Zhang, L. et al. The role of N(6)-methyladenosine (m(6)A) modification in the regulation of circRNAs. Mol. Cancer 19, 105 (2020).","journal-title":"Mol. Cancer"},{"key":"2682_CR79","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1158\/2159-8290.CD-20-0331","volume":"11","author":"D Dixit","year":"2021","unstructured":"Dixit, D. et al. The RNA m6A reader YTHDF2 maintains oncogene expression and is a targetable dependency in glioblastoma stem cells. Cancer Discov. 11, 480\u2013499 (2021).","journal-title":"Cancer Discov."},{"key":"2682_CR80","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/cr.2017.31","volume":"27","author":"Y Yang","year":"2017","unstructured":"Yang, Y. et al. Extensive translation of circular RNAs driven by N(6)-methyladenosine. Cell Res. 27, 626\u2013641 (2017).","journal-title":"Cell Res."},{"key":"2682_CR81","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-019-1685-4","volume":"20","author":"WC Liang","year":"2019","unstructured":"Liang, W. C. et al. Translation of the circular RNA circbeta-catenin promotes liver cancer cell growth through activation of the Wnt pathway. Genome Biol. 20, 84 (2019).","journal-title":"Genome Biol."},{"key":"2682_CR82","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-020-02250-6","volume":"22","author":"X Wu","year":"2021","unstructured":"Wu, X. et al. A novel protein encoded by circular SMO RNA is essential for Hedgehog signaling activation and glioblastoma tumorigenicity. Genome Biol. 22, 33 (2021).","journal-title":"Genome Biol."},{"key":"2682_CR83","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/s41556-021-00639-4","volume":"23","author":"X Gao","year":"2021","unstructured":"Gao, X. et al. Circular RNA-encoded oncogenic E-cadherin variant promotes glioblastoma tumorigenicity through activation of EGFR-STAT3 signalling. Nat. Cell Biol. 23, 278\u2013291 (2021).","journal-title":"Nat. Cell Biol."},{"key":"2682_CR84","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40212-1","volume":"14","author":"J Zhong","year":"2023","unstructured":"Zhong, J. et al. Circular RNA encoded MET variant promotes glioblastoma tumorigenesis. Nat. Commun. 14, 4467 (2023).","journal-title":"Nat. Commun."},{"key":"2682_CR85","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1158\/2159-8290.CD-12-0558","volume":"3","author":"A Bardelli","year":"2013","unstructured":"Bardelli, A. et al. Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. Cancer Discov. 3, 658\u2013673 (2013).","journal-title":"Cancer Discov."},{"key":"2682_CR86","doi-asserted-by":"publisher","first-page":"4046","DOI":"10.1073\/pnas.0509040103","volume":"103","author":"E Gherardi","year":"2006","unstructured":"Gherardi, E. et al. Structural basis of hepatocyte growth factor\/scatter factor and MET signalling. Proc. Natl. Acad. Sci. USA 103, 4046\u20134051 (2006).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2682_CR87","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/sj.onc.1205004","volume":"21","author":"YW Zhang","year":"2002","unstructured":"Zhang, Y. W., Wang, L. M., Jove, R. & Vande Woude, G. F. Requirement of Stat3 signaling for HGF\/SF-Met mediated tumorigenesis. Oncogene 21, 217\u2013226 (2002).","journal-title":"Oncogene"},{"key":"2682_CR88","first-page":"1631","volume":"10","author":"G Pelicci","year":"1995","unstructured":"Pelicci, G. et al. The motogenic and mitogenic responses to HGF are amplified by the Shc adaptor protein. Oncogene 10, 1631\u20131638 (1995).","journal-title":"Oncogene"},{"key":"2682_CR89","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1158\/1535-7163.MCT-16-0472","volume":"16","author":"R Salgia","year":"2017","unstructured":"Salgia, R. MET in lung cancer: biomarker selection based on scientific rationale. Mol. Cancer Ther. 16, 555\u2013565 (2017).","journal-title":"Mol. Cancer Ther."},{"key":"2682_CR90","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1038\/sj.onc.1208327","volume":"24","author":"S Fan","year":"2005","unstructured":"Fan, S. et al. Role of NF-kappaB signaling in hepatocyte growth factor\/scatter factor-mediated cell protection. Oncogene 24, 1749\u20131766 (2005).","journal-title":"Oncogene"},{"key":"2682_CR91","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.semcancer.2017.04.006","volume":"44","author":"E Giovannetti","year":"2017","unstructured":"Giovannetti, E. et al. Never let it go: Stopping key mechanisms underlying metastasis to fight pancreatic cancer. Semin. Cancer Biol. 44, 43\u201359 (2017).","journal-title":"Semin. Cancer Biol."},{"key":"2682_CR92","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/s41568-018-0002-y","volume":"18","author":"PM Comoglio","year":"2018","unstructured":"Comoglio, P. M., Trusolino, L. & Boccaccio, C. Known and novel roles of the MET oncogene in cancer: a coherent approach to targeted therapy. Nat. Rev. Cancer 18, 341\u2013358 (2018).","journal-title":"Nat. Rev. Cancer"},{"key":"2682_CR93","doi-asserted-by":"crossref","unstructured":"Yamaoka, T. et al. Receptor tyrosine kinase-targeted cancer therapy. Int. J. Mol. Sci. 19, 3491 (2018).","DOI":"10.3390\/ijms19113491"},{"key":"2682_CR94","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1016\/j.ejca.2010.02.036","volume":"46","author":"S Previdi","year":"2010","unstructured":"Previdi, S. et al. Interaction between human-breast cancer metastasis and bone microenvironment through activated hepatocyte growth factor\/Met and beta-catenin\/Wnt pathways. Eur. J. Cancer 46, 1679\u20131691 (2010).","journal-title":"Eur. J. Cancer"},{"key":"2682_CR95","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1093\/neuonc\/nos299","volume":"15","author":"KH Kim","year":"2013","unstructured":"Kim, K. H. et al. Wnt\/beta-catenin signaling is a key downstream mediator of MET signaling in glioblastoma stem cells. Neuro Oncol. 15, 161\u2013171 (2013).","journal-title":"Neuro Oncol."},{"key":"2682_CR96","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1158\/0008-5472.CAN-07-5172","volume":"68","author":"JB Tuynman","year":"2008","unstructured":"Tuynman, J. B. et al. Cyclooxygenase-2 inhibition inhibits c-Met kinase activity and Wnt activity in colon cancer. Cancer Res. 68, 1213\u20131220 (2008).","journal-title":"Cancer Res."},{"key":"2682_CR97","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1016\/j.celrep.2013.11.001","volume":"5","author":"JD Holland","year":"2013","unstructured":"Holland, J. D. et al. Combined Wnt\/beta-catenin, Met, and CXCL12\/CXCR4 signals characterize basal breast cancer and predict disease outcome. Cell Rep. 5, 1214\u20131227 (2013).","journal-title":"Cell Rep."},{"key":"2682_CR98","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.ygyno.2013.09.034","volume":"131","author":"RC Arend","year":"2013","unstructured":"Arend, R. C., Londono-Joshi, A. I., Straughn, J. M. Jr. & Buchsbaum, D. J. The Wnt\/beta-catenin pathway in ovarian cancer: a review. Gynecol. Oncol. 131, 772\u2013779 (2013).","journal-title":"Gynecol. Oncol."},{"key":"2682_CR99","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1002\/hep.32693","volume":"77","author":"B Liang","year":"2023","unstructured":"Liang, B. et al. Differential requirement of Hippo cascade during CTNNB1 or AXIN1 mutation-driven hepatocarcinogenesis. Hepatology 77, 1929\u20131942 (2023).","journal-title":"Hepatology"},{"key":"2682_CR100","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1083\/jcb.149.7.1419","volume":"149","author":"U Schaeper","year":"2000","unstructured":"Schaeper, U. et al. Coupling of Gab1 to c-Met, Grb2, and Shp2 mediates biological responses. J. Cell Biol. 149, 1419\u20131432 (2000).","journal-title":"J. Cell Biol."},{"key":"2682_CR101","doi-asserted-by":"publisher","first-page":"31536","DOI":"10.1074\/jbc.M003597200","volume":"275","author":"LS Lock","year":"2000","unstructured":"Lock, L. S., Royal, I., Naujokas, M. A. & Park, M. Identification of an atypical Grb2 carboxyl-terminal SH3 domain binding site in Gab docking proteins reveals Grb2-dependent and -independent recruitment of Gab1 to receptor tyrosine kinases. J. Biol. Chem. 275, 31536\u201331545 (2000).","journal-title":"J. Biol. Chem."},{"key":"2682_CR102","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1128\/MCB.19.3.1784","volume":"19","author":"CR Maroun","year":"1999","unstructured":"Maroun, C. R. et al. The Gab1 PH domain is required for localization of Gab1 at sites of cell-cell contact and epithelial morphogenesis downstream from the met receptor tyrosine kinase. Mol. Cell Biol. 19, 1784\u20131799 (1999).","journal-title":"Mol. Cell Biol."},{"key":"2682_CR103","doi-asserted-by":"publisher","first-page":"8513","DOI":"10.1128\/MCB.20.22.8513-8525.2000","volume":"20","author":"CR Maroun","year":"2000","unstructured":"Maroun, C. R. et al. The tyrosine phosphatase SHP-2 is required for sustained activation of extracellular signal-regulated kinase and epithelial morphogenesis downstream from the met receptor tyrosine kinase. Mol. Cell Biol. 20, 8513\u20138525 (2000).","journal-title":"Mol. Cell Biol."},{"key":"2682_CR104","doi-asserted-by":"publisher","first-page":"33714","DOI":"10.1074\/jbc.273.50.33714","volume":"273","author":"N Rahimi","year":"1998","unstructured":"Rahimi, N. et al. c-Src kinase activity is required for hepatocyte growth factor-induced motility and anchorage-independent growth of mammary carcinoma cells. J. Biol. Chem. 273, 33714\u201333721 (1998).","journal-title":"J. Biol. Chem."},{"key":"2682_CR105","doi-asserted-by":"publisher","first-page":"5350","DOI":"10.1074\/jbc.M410012200","volume":"280","author":"A Montagner","year":"2005","unstructured":"Montagner, A. et al. A novel role for Gab1 and SHP2 in epidermal growth factor-induced Ras activation. J. Biol. Chem. 280, 5350\u20135360 (2005).","journal-title":"J. Biol. Chem."},{"key":"2682_CR106","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1038\/sj.onc.1203514","volume":"19","author":"P Gual","year":"2000","unstructured":"Gual, P. et al. Sustained recruitment of phospholipase C-gamma to Gab1 is required for HGF-induced branching tubulogenesis. Oncogene 19, 1509\u20131518 (2000).","journal-title":"Oncogene"},{"key":"2682_CR107","doi-asserted-by":"publisher","first-page":"7775","DOI":"10.1038\/sj.onc.1203198","volume":"18","author":"M Garcia-Guzman","year":"1999","unstructured":"Garcia-Guzman, M., Dolfi, F., Zeh, K. & Vuori, K. Met-induced JNK activation is mediated by the adapter protein Crk and correlates with the Gab1 - Crk signaling complex formation. Oncogene 18, 7775\u20137786 (1999).","journal-title":"Oncogene"},{"key":"2682_CR108","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/384173a0","volume":"384","author":"KM Weidner","year":"1996","unstructured":"Weidner, K. M. et al. Interaction between Gab1 and the c-Met receptor tyrosine kinase is responsible for epithelial morphogenesis. Nature 384, 173\u2013176 (1996).","journal-title":"Nature"},{"key":"2682_CR109","doi-asserted-by":"publisher","first-page":"3074","DOI":"10.1101\/gad.242602","volume":"16","author":"V Orian-Rousseau","year":"2002","unstructured":"Orian-Rousseau, V. et al. CD44 is required for two consecutive steps in HGF\/c-Met signaling. Genes Dev. 16, 3074\u20133086 (2002).","journal-title":"Genes Dev."},{"key":"2682_CR110","doi-asserted-by":"publisher","first-page":"5131","DOI":"10.1038\/sj.onc.1207650","volume":"23","author":"P Conrotto","year":"2004","unstructured":"Conrotto, P. et al. Interplay between scatter factor receptors and B plexins controls invasive growth. Oncogene 23, 5131\u20135137 (2004).","journal-title":"Oncogene"},{"key":"2682_CR111","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1038\/ncb843","volume":"4","author":"S Giordano","year":"2002","unstructured":"Giordano, S. et al. The semaphorin 4D receptor controls invasive growth by coupling with Met. Nat. Cell Biol. 4, 720\u2013724 (2002).","journal-title":"Nat. Cell Biol."},{"key":"2682_CR112","doi-asserted-by":"publisher","first-page":"4321","DOI":"10.1182\/blood-2004-07-2885","volume":"105","author":"P Conrotto","year":"2005","unstructured":"Conrotto, P. et al. Sema4D induces angiogenesis through Met recruitment by Plexin B1. Blood 105, 4321\u20134329 (2005).","journal-title":"Blood"},{"key":"2682_CR113","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/S0092-8674(01)00567-0","volume":"107","author":"L Trusolino","year":"2001","unstructured":"Trusolino, L., Bertotti, A. & Comoglio, P. M. A signaling adapter function for alpha6beta4 integrin in the control of HGF-dependent invasive growth. Cell 107, 643\u2013654 (2001).","journal-title":"Cell"},{"key":"2682_CR114","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1083\/jcb.200605114","volume":"175","author":"A Bertotti","year":"2006","unstructured":"Bertotti, A., Comoglio, P. M. & Trusolino, L. Beta4 integrin activates a Shp2-Src signaling pathway that sustains HGF-induced anchorage-independent growth. J. Cell Biol. 175, 993\u20131003 (2006).","journal-title":"J. Cell Biol."},{"key":"2682_CR115","doi-asserted-by":"publisher","first-page":"683","DOI":"10.4161\/cc.4.5.1688","volume":"4","author":"D Wickramasinghe","year":"2005","unstructured":"Wickramasinghe, D. & Kong-Beltran, M. Met activation and receptor dimerization in cancer: a role for the Sema domain. Cell Cycle 4, 683\u2013685 (2005).","journal-title":"Cell Cycle"},{"key":"2682_CR116","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01503-1","volume":"21","author":"S Raj","year":"2022","unstructured":"Raj, S. et al. Molecular mechanism(s) of regulation(s) of c-MET\/HGF signaling in head and neck cancer. Mol. Cancer 21, 31 (2022).","journal-title":"Mol. Cancer"},{"key":"2682_CR117","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/nrclinonc.2017.40","volume":"14","author":"CA Bradley","year":"2017","unstructured":"Bradley, C. A. et al. Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges. Nat. Rev. Clin. Oncol. 14, 562\u2013576 (2017).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2682_CR118","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1158\/1535-7163.MCT-05-0175","volume":"5","author":"TW Bauer","year":"2006","unstructured":"Bauer, T. W. et al. Regulatory role of c-Met in insulin-like growth factor-I receptor-mediated migration and invasion of human pancreatic carcinoma cells. Mol. Cancer Ther. 5, 1676\u20131682 (2006).","journal-title":"Mol. Cancer Ther."},{"key":"2682_CR119","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.4161\/cbt.5.9.3315","volume":"5","author":"JL Kissil","year":"2006","unstructured":"Kissil, J. L. & Charest, A. New tools for dissecting RON receptor tyrosine kinase oncogenic signaling. Cancer Biol. Ther. 5, 1187\u20131188 (2006).","journal-title":"Cancer Biol. Ther."},{"key":"2682_CR120","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1158\/0008-5472.CAN-10-2100","volume":"71","author":"S Benvenuti","year":"2011","unstructured":"Benvenuti, S. et al. Ron kinase transphosphorylation sustains MET oncogene addiction. Cancer Res. 71, 1945\u20131955 (2011).","journal-title":"Cancer Res."},{"key":"2682_CR121","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/bjc.2011.322","volume":"105","author":"J Tanizaki","year":"2011","unstructured":"Tanizaki, J., Okamoto, I., Sakai, K. & Nakagawa, K. Differential roles of trans-phosphorylated EGFR, HER2, HER3, and RET as heterodimerisation partners of MET in lung cancer with MET amplification. Br. J. Cancer 105, 807\u2013813 (2011).","journal-title":"Br. J. Cancer"},{"key":"2682_CR122","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/0092-8674(95)90404-2","volume":"80","author":"CH Heldin","year":"1995","unstructured":"Heldin, C. H. Dimerization of cell surface receptors in signal transduction. Cell 80, 213\u2013223 (1995).","journal-title":"Cell"},{"key":"2682_CR123","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.febslet.2004.10.024","volume":"577","author":"D Shida","year":"2004","unstructured":"Shida, D. et al. Sphingosine 1-phosphate transactivates c-Met as well as epidermal growth factor receptor (EGFR) in human gastric cancer cells. FEBS Lett. 577, 333\u2013338 (2004).","journal-title":"FEBS Lett."},{"key":"2682_CR124","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.1038\/sj.onc.1203620","volume":"19","author":"A Follenzi","year":"2000","unstructured":"Follenzi, A. et al. Cross-talk between the proto-oncogenes Met and Ron. Oncogene 19, 3041\u20133049 (2000).","journal-title":"Oncogene"},{"key":"2682_CR125","doi-asserted-by":"publisher","first-page":"15397","DOI":"10.1074\/jbc.RA118.003063","volume":"293","author":"W Li","year":"2018","unstructured":"Li, W. et al. HGF-induced formation of the MET-AXL-ELMO2-DOCK180 complex promotes RAC1 activation, receptor clustering, and cancer cell migration and invasion. J. Biol. Chem. 293, 15397\u201315418 (2018).","journal-title":"J. Biol. Chem."},{"key":"2682_CR126","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.mce.2013.04.018","volume":"374","author":"S Salian-Mehta","year":"2013","unstructured":"Salian-Mehta, S., Xu, M. & Wierman, M. E. AXL and MET crosstalk to promote gonadotropin releasing hormone (GnRH) neuronal cell migration and survival. Mol. Cell Endocrinol. 374, 92\u2013100 (2013).","journal-title":"Mol. Cell Endocrinol."},{"key":"2682_CR127","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1091\/mbc.e04-07-0567","volume":"16","author":"H Khoury","year":"2005","unstructured":"Khoury, H. et al. HGF converts ErbB2\/Neu epithelial morphogenesis to cell invasion. Mol. Biol. Cell 16, 550\u2013561 (2005).","journal-title":"Mol. Biol. Cell"},{"key":"2682_CR128","doi-asserted-by":"publisher","first-page":"8806","DOI":"10.1074\/jbc.275.12.8806","volume":"275","author":"M Jo","year":"2000","unstructured":"Jo, M. et al. Cross-talk between epidermal growth factor receptor and c-Met signal pathways in transformed cells. J. Biol. Chem. 275, 8806\u20138811 (2000).","journal-title":"J. Biol. Chem."},{"key":"2682_CR129","doi-asserted-by":"publisher","first-page":"3625","DOI":"10.1038\/onc.2011.84","volume":"30","author":"AM Dulak","year":"2011","unstructured":"Dulak, A. M. et al. HGF-independent potentiation of EGFR action by c-Met. Oncogene 30, 3625\u20133635 (2011).","journal-title":"Oncogene"},{"key":"2682_CR130","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1038\/nm.2753","volume":"18","author":"H Peinado","year":"2012","unstructured":"Peinado, H. et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat. Med. 18, 883\u2013891 (2012).","journal-title":"Nat. Med."},{"key":"2682_CR131","doi-asserted-by":"publisher","first-page":"2821","DOI":"10.1182\/blood-2015-07-658823","volume":"126","author":"L Dai","year":"2015","unstructured":"Dai, L. et al. Targeting HGF\/c-MET induces cell cycle arrest, DNA damage, and apoptosis for primary effusion lymphoma. Blood 126, 2821\u20132831 (2015).","journal-title":"Blood"},{"key":"2682_CR132","first-page":"147","volume":"1","author":"MF Di Renzo","year":"1995","unstructured":"Di Renzo, M. F. et al. Overexpression and amplification of the met\/HGF receptor gene during the progression of colorectal cancer. Clin. Cancer Res. 1, 147\u2013154 (1995).","journal-title":"Clin. Cancer Res."},{"key":"2682_CR133","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1046\/j.1440-1827.2001.01182.x","volume":"51","author":"G Edakuni","year":"2001","unstructured":"Edakuni, G. et al. Expression of the hepatocyte growth factor\/c-Met pathway is increased at the cancer front in breast carcinoma. Pathol. Int. 51, 172\u2013178 (2001).","journal-title":"Pathol. Int."},{"key":"2682_CR134","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1158\/1078-0432.CCR-12-2791","volume":"19","author":"L Goyal","year":"2013","unstructured":"Goyal, L., Muzumdar, M. D. & Zhu, A. X. Targeting the HGF\/c-MET pathway in hepatocellular carcinoma. Clin. Cancer Res. 19, 2310\u20132318 (2013).","journal-title":"Clin. Cancer Res."},{"key":"2682_CR135","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1002\/cncr.28454","volume":"120","author":"X An","year":"2014","unstructured":"An, X. et al. MET amplification is not rare and predicts unfavorable clinical outcomes in patients with recurrent\/metastatic gastric cancer after chemotherapy. Cancer 120, 675\u2013682 (2014).","journal-title":"Cancer"},{"key":"2682_CR136","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms8174","volume":"6","author":"I Yeh","year":"2015","unstructured":"Yeh, I. et al. Activating MET kinase rearrangements in melanoma and Spitz tumours. Nat. Commun. 6, 7174 (2015).","journal-title":"Nat. Commun."},{"key":"2682_CR137","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1101\/gr.165126.113","volume":"24","author":"ZS Bao","year":"2014","unstructured":"Bao, Z. S. et al. RNA-seq of 272 gliomas revealed a novel, recurrent PTPRZ1-MET fusion transcript in secondary glioblastomas. Genome Res. 24, 1765\u20131773 (2014).","journal-title":"Genome Res."},{"key":"2682_CR138","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1038\/nm.4204","volume":"22","author":"International Cancer Genome Consortium PedBrain Tumor, P","year":"2016","unstructured":"International Cancer Genome Consortium PedBrain Tumor, P Recurrent MET fusion genes represent a drug target in pediatric glioblastoma. Nat. Med. 22, 1314\u20131320 (2016).","journal-title":"Nat. Med."},{"key":"2682_CR139","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-03999-7","volume":"21","author":"D Sun","year":"2023","unstructured":"Sun, D. et al. Identification of MET fusions as novel therapeutic targets sensitive to MET inhibitors in lung cancer. J. Transl. Med. 21, 150 (2023).","journal-title":"J. Transl. Med."},{"key":"2682_CR140","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1080\/13543784.2020.1699532","volume":"29","author":"H Oliveres","year":"2020","unstructured":"Oliveres, H., Pineda, E. & Maurel, J. MET inhibitors in cancer: pitfalls and challenges. Expert Opin. Investig. Drugs 29, 73\u201385 (2020).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"2682_CR141","doi-asserted-by":"crossref","unstructured":"Davies, K. D. et al. Dramatic response to crizotinib in a patient with lung cancer positive for an HLA-DRB1-MET gene fusion. JCO Precis. Oncol. 2017, PO.17.00117 (2017).","DOI":"10.1200\/PO.17.00117"},{"key":"2682_CR142","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/s41571-020-0377-z","volume":"17","author":"R Guo","year":"2020","unstructured":"Guo, R. et al. MET-dependent solid tumours - molecular diagnosis and targeted therapy. Nat. Rev. Clin. Oncol. 17, 569\u2013587 (2020).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2682_CR143","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.molonc.2014.08.015","volume":"9","author":"PR Gavine","year":"2015","unstructured":"Gavine, P. R. et al. Volitinib, a potent and highly selective c-Met inhibitor, effectively blocks c-Met signaling and growth in c-MET amplified gastric cancer patient-derived tumor xenograft models. Mol. Oncol. 9, 323\u2013333 (2015).","journal-title":"Mol. Oncol."},{"key":"2682_CR144","doi-asserted-by":"publisher","first-page":"4292","DOI":"10.1158\/1078-0432.CCR-09-0599","volume":"15","author":"AL Russo","year":"2009","unstructured":"Russo, A. L. et al. Urine analysis and protein networking identify met as a marker of metastatic prostate cancer. Clin. Cancer Res. 15, 4292\u20134298 (2009).","journal-title":"Clin. Cancer Res."},{"key":"2682_CR145","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1038\/nm.2819","volume":"18","author":"A Kentsis","year":"2012","unstructured":"Kentsis, A. et al. Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia. Nat. Med. 18, 1118\u20131122 (2012).","journal-title":"Nat. Med."},{"key":"2682_CR146","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.pharmthera.2013.12.014","volume":"142","author":"CR Maroun","year":"2014","unstructured":"Maroun, C. R. & Rowlands, T. The Met receptor tyrosine kinase: a key player in oncogenesis and drug resistance. Pharm. Ther. 142, 316\u2013338 (2014).","journal-title":"Pharm. Ther."},{"key":"2682_CR147","doi-asserted-by":"publisher","DOI":"10.1186\/s40169-019-0226-9","volume":"8","author":"SK Daniel","year":"2019","unstructured":"Daniel, S. K., Sullivan, K. M., Labadie, K. P. & Pillarisetty, V. G. Hypoxia as a barrier to immunotherapy in pancreatic adenocarcinoma. Clin. Transl. Med. 8, 10 (2019).","journal-title":"Clin. Transl. Med."},{"key":"2682_CR148","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S1535-6108(03)00085-0","volume":"3","author":"S Pennacchietti","year":"2003","unstructured":"Pennacchietti, S. et al. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 3, 347\u2013361 (2003).","journal-title":"Cancer Cell"},{"key":"2682_CR149","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1002\/hep.30811","volume":"71","author":"JC Nault","year":"2020","unstructured":"Nault, J. C. et al. Clinical impact of genomic diversity from early to advanced hepatocellular carcinoma. Hepatology 71, 164\u2013182 (2020).","journal-title":"Hepatology"},{"key":"2682_CR150","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1158\/1078-0432.CCR-18-2293","volume":"25","author":"JJ Harding","year":"2019","unstructured":"Harding, J. J. et al. Prospective genotyping of hepatocellular carcinoma: clinical implications of next-generation sequencing for matching patients to targeted and immune therapies. Clin. Cancer Res. 25, 2116\u20132126 (2019).","journal-title":"Clin. Cancer Res."},{"key":"2682_CR151","first-page":"5179","volume":"33","author":"SJ Lee","year":"2013","unstructured":"Lee, S. J. et al. A survey of c-MET expression and amplification in 287 patients with hepatocellular carcinoma. Anticancer Res. 33, 5179\u20135186 (2013).","journal-title":"Anticancer Res."},{"key":"2682_CR152","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s10147-011-0361-9","volume":"18","author":"S Kondo","year":"2013","unstructured":"Kondo, S. et al. Clinical impact of c-Met expression and its gene amplification in hepatocellular carcinoma. Int. J. Clin. Oncol. 18, 207\u2013213 (2013).","journal-title":"Int. J. Clin. Oncol."},{"key":"2682_CR153","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.dld.2006.03.007","volume":"38","author":"F Wu","year":"2006","unstructured":"Wu, F. et al. The clinical value of hepatocyte growth factor and its receptor-c-met for liver cancer patients with hepatectomy. Dig. Liver Dis. 38, 490\u2013497 (2006).","journal-title":"Dig. Liver Dis."},{"key":"2682_CR154","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1002\/1097-0215(20000901)87:5<644::AID-IJC4>3.0.CO;2-W","volume":"87","author":"D Tavian","year":"2000","unstructured":"Tavian, D. et al. u-PA and c-MET mRNA expression is co-ordinately enhanced while hepatocyte growth factor mRNA is down-regulated in human hepatocellular carcinoma. Int. J. Cancer 87, 644\u2013649 (2000).","journal-title":"Int. J. Cancer"},{"key":"2682_CR155","doi-asserted-by":"publisher","first-page":"3000","DOI":"10.1093\/annonc\/mdx527","volume":"28","author":"P Schoffski","year":"2017","unstructured":"Schoffski, P. et al. Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 \u2018CREATE\u2019. Ann. Oncol. 28, 3000\u20133008 (2017).","journal-title":"Ann. Oncol."},{"key":"2682_CR156","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1158\/0008-5472.CAN-09-1121","volume":"70","author":"IJ Davis","year":"2010","unstructured":"Davis, I. J. et al. Identification of the receptor tyrosine kinase c-Met and its ligand, hepatocyte growth factor, as therapeutic targets in clear cell sarcoma. Cancer Res. 70, 639\u2013645 (2010).","journal-title":"Cancer Res."},{"key":"2682_CR157","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1093\/carcin\/bgp085","volume":"30","author":"M Provencal","year":"2009","unstructured":"Provencal, M. et al. c-Met activation in medulloblastoma induces tissue factor expression and activity: effects on cell migration. Carcinogenesis 30, 1089\u20131096 (2009).","journal-title":"Carcinogenesis"},{"key":"2682_CR158","doi-asserted-by":"publisher","first-page":"188869","DOI":"10.1016\/j.bbcan.2023.188869","volume":"1878","author":"R Sharma","year":"2023","unstructured":"Sharma, R. & Malviya, R. Correlation between hypoxia and HGF\/c-MET expression in the management of pancreatic cancer. Biochim. Biophys. Acta Rev. Cancer 1878, 188869 (2023).","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"2682_CR159","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s13046-018-0750-2","volume":"37","author":"Y Zhang","year":"2018","unstructured":"Zhang, Y. et al. The dual blockade of MET and VEGFR2 signaling demonstrates pronounced inhibition on tumor growth and metastasis of hepatocellular carcinoma. J. Exp. Clin. Cancer Res. 37, 93 (2018).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2682_CR160","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1158\/1535-7163.MCT-12-0290","volume":"11","author":"R Dienstmann","year":"2012","unstructured":"Dienstmann, R. et al. Molecular profiling of patients with colorectal cancer and matched targeted therapy in phase I clinical trials. Mol. Cancer Ther. 11, 2062\u20132071 (2012).","journal-title":"Mol. Cancer Ther."},{"key":"2682_CR161","first-page":"76","volume":"57","author":"S Osada","year":"2010","unstructured":"Osada, S. et al. Effect of hepatocyte growth factor on progression of liver metastasis in colorectal cancer. Hepatogastroenterology 57, 76\u201380 (2010).","journal-title":"Hepatogastroenterology"},{"key":"2682_CR162","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.canlet.2008.02.049","volume":"265","author":"ZS Zeng","year":"2008","unstructured":"Zeng, Z. S. et al. c-Met gene amplification is associated with advanced stage colorectal cancer and liver metastases. Cancer Lett. 265, 258\u2013269 (2008).","journal-title":"Cancer Lett."},{"key":"2682_CR163","doi-asserted-by":"publisher","first-page":"e22316","DOI":"10.1002\/jbt.22316","volume":"33","author":"JF Yao","year":"2019","unstructured":"Yao, J. F. et al. Role of HGF\/c-Met in the treatment of colorectal cancer with liver metastasis. J. Biochem. Mol. Toxicol. 33, e22316 (2019).","journal-title":"J. Biochem. Mol. Toxicol."},{"key":"2682_CR164","doi-asserted-by":"publisher","first-page":"3522","DOI":"10.1038\/s41388-020-1233-4","volume":"39","author":"F Du","year":"2020","unstructured":"Du, F. et al. SOX13 promotes colorectal cancer metastasis by transactivating SNAI2 and c-MET. Oncogene 39, 3522\u20133540 (2020).","journal-title":"Oncogene"},{"key":"2682_CR165","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1007\/s10620-018-4915-9","volume":"63","author":"Y Luo","year":"2018","unstructured":"Luo, Y. et al. Long noncoding RNA GAPLINC promotes cells migration and invasion in colorectal cancer cell by regulating miR-34a\/c-MET signal pathway. Dig. Dis. Sci. 63, 890\u2013899 (2018).","journal-title":"Dig. Dis. Sci."},{"key":"2682_CR166","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0839-4","volume":"17","author":"M Shen","year":"2018","unstructured":"Shen, M. et al. Met is involved in TIGAR-regulated metastasis of non-small-cell lung cancer. Mol. Cancer 17, 88 (2018).","journal-title":"Mol. Cancer"},{"key":"2682_CR167","doi-asserted-by":"publisher","first-page":"2885","DOI":"10.1038\/sj.emboj.7600763","volume":"24","author":"K Kajiya","year":"2005","unstructured":"Kajiya, K. et al. Hepatocyte growth factor promotes lymphatic vessel formation and function. EMBO J. 24, 2885\u20132895 (2005).","journal-title":"EMBO J."},{"key":"2682_CR168","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/j.1349-7006.2007.00640.x","volume":"99","author":"Y Nakamura","year":"2008","unstructured":"Nakamura, Y. et al. Constitutive activation of c-Met is correlated with c-Met overexpression and dependent on cell-matrix adhesion in lung adenocarcinoma cell lines. Cancer Sci. 99, 14\u201322 (2008).","journal-title":"Cancer Sci."},{"key":"2682_CR169","doi-asserted-by":"publisher","first-page":"5287","DOI":"10.1200\/JCO.2009.23.5556","volume":"27","author":"R Roy","year":"2009","unstructured":"Roy, R., Yang, J. & Moses, M. A. Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J. Clin. Oncol. 27, 5287\u20135297 (2009).","journal-title":"J. Clin. Oncol."},{"key":"2682_CR170","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.1158\/0008-5472.CAN-09-2448","volume":"70","author":"ST Cha","year":"2010","unstructured":"Cha, S. T. et al. MicroRNA-519c suppresses hypoxia-inducible factor-1alpha expression and tumor angiogenesis. Cancer Res. 70, 2675\u20132685 (2010).","journal-title":"Cancer Res."},{"key":"2682_CR171","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ccr.2004.05.032","volume":"6","author":"P Michieli","year":"2004","unstructured":"Michieli, P. et al. Targeting the tumor and its microenvironment by a dual-function decoy Met receptor. Cancer Cell 6, 61\u201373 (2004).","journal-title":"Cancer Cell"},{"key":"2682_CR172","doi-asserted-by":"publisher","first-page":"4816","DOI":"10.1182\/blood-2002-06-1731","volume":"101","author":"S Ding","year":"2003","unstructured":"Ding, S., Merkulova-Rainon, T., Han, Z. C. & Tobelem, G. HGF receptor up-regulation contributes to the angiogenic phenotype of human endothelial cells and promotes angiogenesis in vitro. Blood 101, 4816\u20134822 (2003).","journal-title":"Blood"},{"key":"2682_CR173","doi-asserted-by":"publisher","first-page":"8009","DOI":"10.1158\/0008-5472.CAN-08-4889","volume":"69","author":"F Qian","year":"2009","unstructured":"Qian, F. et al. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases. Cancer Res. 69, 8009\u20138016 (2009).","journal-title":"Cancer Res."},{"key":"2682_CR174","doi-asserted-by":"publisher","first-page":"5489","DOI":"10.1158\/1078-0432.CCR-16-3216","volume":"23","author":"T Cascone","year":"2017","unstructured":"Cascone, T. et al. The HGF\/c-MET pathway is a driver and biomarker of VEGFR-inhibitor resistance and vascular remodeling in non-small cell lung cancer. Clin. Cancer Res. 23, 5489\u20135501 (2017).","journal-title":"Clin. Cancer Res."},{"key":"2682_CR175","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2015.274","volume":"7","author":"X Xu","year":"2016","unstructured":"Xu, X. et al. c-Met and CREB1 are involved in miR-433-mediated inhibition of the epithelial-mesenchymal transition in bladder cancer by regulating Akt\/GSK-3beta\/Snail signaling. Cell Death Dis. 7, e2088 (2016).","journal-title":"Cell Death Dis."},{"key":"2682_CR176","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12241-2","volume":"10","author":"WJ Sim","year":"2019","unstructured":"Sim, W. J. et al. c-Met activation leads to the establishment of a TGFbeta-receptor regulatory network in bladder cancer progression. Nat. Commun. 10, 4349 (2019).","journal-title":"Nat. Commun."},{"key":"2682_CR177","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1016\/j.celrep.2014.05.032","volume":"7","author":"S Van Schaeybroeck","year":"2014","unstructured":"Van Schaeybroeck, S. et al. ADAM17-dependent c-MET-STAT3 signaling mediates resistance to MEK inhibitors in KRAS mutant colorectal cancer. Cell Rep. 7, 1940\u20131955 (2014).","journal-title":"Cell Rep."},{"key":"2682_CR178","doi-asserted-by":"publisher","first-page":"4408","DOI":"10.1158\/0008-5472.CAN-06-4443","volume":"67","author":"HY Zou","year":"2007","unstructured":"Zou, H. Y. et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res. 67, 4408\u20134417 (2007).","journal-title":"Cancer Res."},{"key":"2682_CR179","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1159\/000065477","volume":"63","author":"H Amemiya","year":"2002","unstructured":"Amemiya, H. et al. c-Met expression in gastric cancer with liver metastasis. Oncology 63, 286\u2013296 (2002).","journal-title":"Oncology"},{"key":"2682_CR180","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.canlet.2013.02.002","volume":"335","author":"X Wu","year":"2013","unstructured":"Wu, X. et al. Hepatocyte growth factor activates tumor stromal fibroblasts to promote tumorigenesis in gastric cancer. Cancer Lett. 335, 128\u2013135 (2013).","journal-title":"Cancer Lett."},{"key":"2682_CR181","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1002\/(SICI)1097-0142(19980601)82:11<2112::AID-CNCR5>3.0.CO;2-X","volume":"82","author":"K Taniguchi","year":"1998","unstructured":"Taniguchi, K. et al. The relation between the growth patterns of gastric carcinoma and the expression of hepatocyte growth factor receptor (c-met), autocrine motility factor receptor, and urokinase-type plasminogen activator receptor. Cancer 82, 2112\u20132122 (1998).","journal-title":"Cancer"},{"key":"2682_CR182","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1034\/j.1600-0463.2000.d01-44.x","volume":"108","author":"WS Park","year":"2000","unstructured":"Park, W. S. et al. Absence of mutations in the kinase domain of the Met gene and frequent expression of Met and HGF\/SF protein in primary gastric carcinomas. APMIS 108, 195\u2013200 (2000).","journal-title":"APMIS"},{"key":"2682_CR183","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1002\/ijc.26330","volume":"130","author":"Y Toiyama","year":"2012","unstructured":"Toiyama, Y. et al. Co-expression of hepatocyte growth factor and c-Met predicts peritoneal dissemination established by autocrine hepatocyte growth factor\/c-Met signaling in gastric cancer. Int. J. Cancer 130, 2912\u20132921 (2012).","journal-title":"Int. J. Cancer"},{"key":"2682_CR184","first-page":"1480","volume":"9","author":"H Takeuchi","year":"2003","unstructured":"Takeuchi, H. et al. c-MET expression level in primary colon cancer: a predictor of tumor invasion and lymph node metastases. Clin. Cancer Res. 9, 1480\u20131488 (2003).","journal-title":"Clin. Cancer Res."},{"key":"2682_CR185","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.bbadis.2017.12.021","volume":"1864","author":"Y Yi","year":"2018","unstructured":"Yi, Y. et al. Cancer-associated fibroblasts promote epithelial-mesenchymal transition and EGFR-TKI resistance of non-small cell lung cancers via HGF\/IGF-1\/ANXA2 signaling. Biochim Biophys. Acta Mol. Basis Dis. 1864, 793\u2013803 (2018).","journal-title":"Biochim Biophys. Acta Mol. Basis Dis."},{"key":"2682_CR186","doi-asserted-by":"publisher","first-page":"9479","DOI":"10.1158\/0008-5472.CAN-08-1643","volume":"68","author":"S Yano","year":"2008","unstructured":"Yano, S. et al. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res. 68, 9479\u20139487 (2008).","journal-title":"Cancer Res."},{"key":"2682_CR187","first-page":"618","volume":"6","author":"MF Gayyed","year":"2015","unstructured":"Gayyed, M. F., Abd El-Maqsoud, N. M., El-Hameed El-Heeny, A. A. & Mohammed, M. F. c-MET expression in colorectal adenomas and primary carcinomas with its corresponding metastases. J. Gastrointest. Oncol. 6, 618\u2013627 (2015).","journal-title":"J. Gastrointest. Oncol."},{"key":"2682_CR188","doi-asserted-by":"publisher","first-page":"548","DOI":"10.7150\/ijms.5191","volume":"10","author":"YL Sun","year":"2013","unstructured":"Sun, Y. L. et al. Expression of HGF and Met in human tissues of colorectal cancers: biological and clinical implications for synchronous liver metastasis. Int. J. Med. Sci. 10, 548\u2013559 (2013).","journal-title":"Int. J. Med. Sci."},{"key":"2682_CR189","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/BF00121166","volume":"11","author":"WG Jiang","year":"1993","unstructured":"Jiang, W. G. et al. Regulation of spreading and growth of colon cancer cells by hepatocyte growth factor. Clin. Exp. Metastasis 11, 235\u2013242 (1993).","journal-title":"Clin. Exp. Metastasis"},{"key":"2682_CR190","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/bjc.2017.196","volume":"117","author":"D Oddo","year":"2017","unstructured":"Oddo, D. et al. Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer. Br. J. Cancer 117, 347\u2013352 (2017).","journal-title":"Br. J. Cancer"},{"key":"2682_CR191","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1158\/0008-5472.CAN-13-2340-T","volume":"74","author":"P Luraghi","year":"2014","unstructured":"Luraghi, P. et al. MET signaling in colon cancer stem-like cells blunts the therapeutic response to EGFR inhibitors. Cancer Res. 74, 1857\u20131869 (2014).","journal-title":"Cancer Res."},{"key":"2682_CR192","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/nature11183","volume":"487","author":"R Straussman","year":"2012","unstructured":"Straussman, R. et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 487, 500\u2013504 (2012).","journal-title":"Nature"},{"key":"2682_CR193","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1161\/01.CIR.0000143052.45956.71","volume":"110","author":"K Yamaura","year":"2004","unstructured":"Yamaura, K. et al. Suppression of acute and chronic rejection by hepatocyte growth factor in a murine model of cardiac transplantation: induction of tolerance and prevention of cardiac allograft vasculopathy. Circulation 110, 1650\u20131657 (2004).","journal-title":"Circulation"},{"key":"2682_CR194","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.mcn.2004.07.007","volume":"27","author":"J Thompson","year":"2004","unstructured":"Thompson, J. et al. HGF promotes survival and growth of maturing sympathetic neurons by PI-3 kinase- and MAP kinase-dependent mechanisms. Mol. Cell Neurosci. 27, 441\u2013452 (2004).","journal-title":"Mol. Cell Neurosci."},{"key":"2682_CR195","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-021-02051-2","volume":"21","author":"Z Shen","year":"2021","unstructured":"Shen, Z. et al. Molecular mechanism study of HGF\/c-MET pathway activation and immune regulation for a tumor diagnosis model. Cancer Cell Int. 21, 374 (2021).","journal-title":"Cancer Cell Int."},{"key":"2682_CR196","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.cyto.2015.12.013","volume":"82","author":"S Ilangumaran","year":"2016","unstructured":"Ilangumaran, S., Villalobos-Hernandez, A., Bobbala, D. & Ramanathan, S. The hepatocyte growth factor (HGF)-MET receptor tyrosine kinase signaling pathway: diverse roles in modulating immune cell functions. Cytokine 82, 125\u2013139 (2016).","journal-title":"Cytokine"},{"key":"2682_CR197","doi-asserted-by":"publisher","first-page":"3658","DOI":"10.1158\/1078-0432.CCR-03-0640","volume":"10","author":"K Schag","year":"2004","unstructured":"Schag, K. et al. Identification of C-met oncogene as a broadly expressed tumor-associated antigen recognized by cytotoxic T-lymphocytes. Clin. Cancer Res. 10, 3658\u20133666 (2004).","journal-title":"Clin. Cancer Res."},{"key":"2682_CR198","doi-asserted-by":"publisher","first-page":"3812","DOI":"10.1182\/blood-2006-07-035972","volume":"109","author":"K Fischer","year":"2007","unstructured":"Fischer, K. et al. Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood 109, 3812\u20133819 (2007).","journal-title":"Blood"},{"key":"2682_CR199","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.immuni.2017.09.012","volume":"47","author":"N Glodde","year":"2017","unstructured":"Glodde, N. et al. Reactive neutrophil responses dependent on the receptor tyrosine kinase c-MET limit cancer immunotherapy. Immunity 47, 789\u2013802 e789, (2017).","journal-title":"Immunity"},{"key":"2682_CR200","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1186\/s13287-019-1488-2","volume":"10","author":"Z Lu","year":"2019","unstructured":"Lu, Z. et al. Mesenchymal stem cells induce dendritic cell immune tolerance via paracrine hepatocyte growth factor to alleviate acute lung injury. Stem Cell Res. Ther. 10, 372 (2019).","journal-title":"Stem Cell Res. Ther."},{"key":"2682_CR201","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1002\/1521-4141(200207)32:7<1832::AID-IMMU1832>3.0.CO;2-2","volume":"32","author":"SM Kurz","year":"2002","unstructured":"Kurz, S. M. et al. The impact of c-met\/scatter factor receptor on dendritic cell migration. Eur. J. Immunol. 32, 1832\u20131838 (2002).","journal-title":"Eur. J. Immunol."},{"key":"2682_CR202","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/j.biocel.2011.04.006","volume":"43","author":"E Singhal","year":"2011","unstructured":"Singhal, E. & Sen, P. Hepatocyte growth factor-induced c-Src-phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin pathway inhibits dendritic cell activation by blocking IkappaB kinase activity. Int. J. Biochem. Cell Biol. 43, 1134\u20131146 (2011).","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"2682_CR203","doi-asserted-by":"publisher","first-page":"32054","DOI":"10.1074\/jbc.M111.271247","volume":"286","author":"E Singhal","year":"2011","unstructured":"Singhal, E., Kumar, P. & Sen, P. A novel role for Bruton\u2019s tyrosine kinase in hepatocyte growth factor-mediated immunoregulation of dendritic cells. J. Biol. Chem. 286, 32054\u201332063 (2011).","journal-title":"J. Biol. Chem."},{"key":"2682_CR204","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1182\/blood-2005-08-3141","volume":"108","author":"S Rutella","year":"2006","unstructured":"Rutella, S. et al. Hepatocyte growth factor favors monocyte differentiation into regulatory interleukin (IL)-10\u2009+\u2009+\u2009IL-12low\/neg accessory cells with dendritic-cell features. Blood 108, 218\u2013227 (2006).","journal-title":"Blood"},{"key":"2682_CR205","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.4049\/jimmunol.1200729","volume":"189","author":"JH Baek","year":"2012","unstructured":"Baek, J. H., Birchmeier, C., Zenke, M. & Hieronymus, T. The HGF receptor\/Met tyrosine kinase is a key regulator of dendritic cell migration in skin immunity. J. Immunol. 189, 1699\u20131707 (2012).","journal-title":"J. Immunol."},{"key":"2682_CR206","doi-asserted-by":"publisher","first-page":"6424","DOI":"10.1073\/pnas.0912437107","volume":"107","author":"M Benkhoucha","year":"2010","unstructured":"Benkhoucha, M. et al. Hepatocyte growth factor inhibits CNS autoimmunity by inducing tolerogenic dendritic cells and CD25+Foxp3+ regulatory T cells. Proc. Natl. Acad. Sci. USA 107, 6424\u20136429 (2010).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2682_CR207","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1002\/(SICI)1097-0215(19970516)71:4<630::AID-IJC20>3.0.CO;2-E","volume":"71","author":"FY Yue","year":"1997","unstructured":"Yue, F. Y. et al. Interleukin-10 is a growth factor for human melanoma cells and down-regulates HLA class-I, HLA class-II and ICAM-1 molecules. Int. J. Cancer 71, 630\u2013637 (1997).","journal-title":"Int. J. Cancer"},{"key":"2682_CR208","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1002\/eji.1830250722","volume":"25","author":"B Ludewig","year":"1995","unstructured":"Ludewig, B. et al. Spontaneous apoptosis of dendritic cells is efficiently inhibited by TRAP (CD40-ligand) and TNF-alpha, but strongly enhanced by interleukin-10. Eur. J. Immunol. 25, 1943\u20131950 (1995).","journal-title":"Eur. J. Immunol."},{"key":"2682_CR209","doi-asserted-by":"publisher","first-page":"e2312855121","DOI":"10.1073\/pnas.2312855121","volume":"121","author":"W Jing","year":"2024","unstructured":"Jing, W. et al. Tumor-neutrophil cross talk orchestrates the tumor microenvironment to determine the bladder cancer progression. Proc. Natl. Acad. Sci. USA 121, e2312855121 (2024).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2682_CR210","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/nature14407","volume":"522","author":"V Finisguerra","year":"2015","unstructured":"Finisguerra, V. et al. MET is required for the recruitment of anti-tumoural neutrophils. Nature 522, 349\u2013353 (2015).","journal-title":"Nature"},{"key":"2682_CR211","doi-asserted-by":"crossref","unstructured":"Yao, S. et al. Unveiling the role of HGF\/c-Met signaling in non-small cell lung cancer tumor microenvironment. Int. J. Mol. Sci. 25, 9101 (2024).","DOI":"10.3390\/ijms25169101"},{"key":"2682_CR212","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1189\/jlb.3A0513-242R","volume":"96","author":"PM Chen","year":"2014","unstructured":"Chen, P. M. et al. Induction of immunomodulatory monocytes by human mesenchymal stem cell-derived hepatocyte growth factor through ERK1\/2. J. Leukoc. Biol. 96, 295\u2013303 (2014).","journal-title":"J. Leukoc. Biol."},{"key":"2682_CR213","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1016\/S0140-6736(16)00587-0","volume":"387","author":"L Fehrenbacher","year":"2016","unstructured":"Fehrenbacher, L. et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet 387, 1837\u20131846 (2016).","journal-title":"Lancet"},{"key":"2682_CR214","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1038\/s41423-020-0487-7","volume":"18","author":"Y Sun","year":"2021","unstructured":"Sun, Y. et al. PD-L1(+) exosomes from bone marrow-derived cells of tumor-bearing mice inhibit antitumor immunity. Cell Mol. Immunol. 18, 2402\u20132409 (2021).","journal-title":"Cell Mol. Immunol."},{"key":"2682_CR215","doi-asserted-by":"crossref","unstructured":"Ahn, H. K. et al. MET receptor tyrosine kinase regulates the expression of co-stimulatory and co-inhibitory molecules in tumor cells and contributes to PD-L1-mediated suppression of immune cell function. Int. J. Mol. Sci. 20, 4287 (2019).","DOI":"10.3390\/ijms20174287"},{"key":"2682_CR216","doi-asserted-by":"publisher","first-page":"4579","DOI":"10.1158\/1078-0432.CCR-18-0267","volume":"24","author":"M Saigi","year":"2018","unstructured":"Saigi, M. et al. MET-oncogenic and JAK2-inactivating alterations are independent factors that affect regulation of PD-L1 expression in lung cancer. Clin. Cancer Res. 24, 4579\u20134587 (2018).","journal-title":"Clin. Cancer Res."},{"key":"2682_CR217","doi-asserted-by":"publisher","first-page":"4079","DOI":"10.1158\/0008-5472.CAN-22-0770","volume":"82","author":"R Yoshida","year":"2022","unstructured":"Yoshida, R. et al. MET-induced CD73 restrains STING-mediated immunogenicity of EGFR-mutant lung cancer. Cancer Res. 82, 4079\u20134092 (2022).","journal-title":"Cancer Res."},{"key":"2682_CR218","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1186\/s13046-021-02055-w","volume":"40","author":"E Li","year":"2021","unstructured":"Li, E., Huang, X., Zhang, G. & Liang, T. Combinational blockade of MET and PD-L1 improves pancreatic cancer immunotherapeutic efficacy. J. Exp. Clin. Cancer Res. 40, 279 (2021).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2682_CR219","doi-asserted-by":"publisher","first-page":"8110","DOI":"10.1074\/jbc.M114.612689","volume":"290","author":"M Balan","year":"2015","unstructured":"Balan, M. et al. Novel roles of c-Met in the survival of renal cancer cells through the regulation of HO-1 and PD-L1 expression. J. Biol. Chem. 290, 8110\u20138120 (2015).","journal-title":"J. Biol. Chem."},{"key":"2682_CR220","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s00109-022-02179-2","volume":"100","author":"R Xu","year":"2022","unstructured":"Xu, R. et al. c-Met up-regulates the expression of PD-L1 through MAPK\/NF-kappaBp65 pathway. J. Mol. Med. 100, 585\u2013598 (2022).","journal-title":"J. Mol. Med."},{"key":"2682_CR221","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-1073-4","volume":"18","author":"S Peng","year":"2019","unstructured":"Peng, S. et al. EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression. Mol. Cancer 18, 165 (2019).","journal-title":"Mol. Cancer"},{"key":"2682_CR222","doi-asserted-by":"crossref","unstructured":"Wang, Q. W. et al. MET overexpression contributes to STAT4-PD-L1 signaling activation associated with tumor-associated, macrophages-mediated immunosuppression in primary glioblastomas. J. Immunother. Cancer 9, e002451 (2021).","DOI":"10.1136\/jitc-2021-002451"},{"key":"2682_CR223","doi-asserted-by":"publisher","first-page":"7011","DOI":"10.1158\/0008-5472.CAN-04-1364","volume":"64","author":"R Galli","year":"2004","unstructured":"Galli, R. et al. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res. 64, 7011\u20137021 (2004).","journal-title":"Cancer Res."},{"key":"2682_CR224","doi-asserted-by":"publisher","first-page":"10946","DOI":"10.1158\/0008-5472.CAN-05-2018","volume":"65","author":"AT Collins","year":"2005","unstructured":"Collins, A. T. et al. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 65, 10946\u201310951 (2005).","journal-title":"Cancer Res."},{"key":"2682_CR225","doi-asserted-by":"publisher","first-page":"3983","DOI":"10.1073\/pnas.0530291100","volume":"100","author":"M Al-Hajj","year":"2003","unstructured":"Al-Hajj, M. et al. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. USA 100, 3983\u20133988 (2003).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2682_CR226","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/nature05372","volume":"445","author":"CA O\u2019Brien","year":"2007","unstructured":"O\u2019Brien, C. A., Pollett, A., Gallinger, S. & Dick, J. E. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445, 106\u2013110 (2007).","journal-title":"Nature"},{"key":"2682_CR227","doi-asserted-by":"publisher","first-page":"9951","DOI":"10.1073\/pnas.1016912108","volume":"108","author":"Y Li","year":"2011","unstructured":"Li, Y. et al. c-Met signaling induces a reprogramming network and supports the glioblastoma stem-like phenotype. Proc. Natl. Acad. Sci. USA 108, 9951\u20139956 (2011).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2682_CR228","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-4529-9","volume":"18","author":"WC Huang","year":"2018","unstructured":"Huang, W. C. et al. IFI44L is a novel tumor suppressor in human hepatocellular carcinoma affecting cancer stemness, metastasis, and drug resistance via regulating met\/Src signaling pathway. BMC Cancer 18, 609 (2018).","journal-title":"BMC Cancer"},{"key":"2682_CR229","doi-asserted-by":"publisher","first-page":"5","DOI":"10.21037\/atm.2016.12.67","volume":"5","author":"HM Jeon","year":"2017","unstructured":"Jeon, H. M. & Lee, J. MET: roles in epithelial-mesenchymal transition and cancer stemness. Ann. Transl. Med. 5, 5 (2017).","journal-title":"Ann. Transl. Med."},{"key":"2682_CR230","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.stem.2018.11.017","volume":"24","author":"C Saygin","year":"2019","unstructured":"Saygin, C. et al. Targeting cancer stemness in the clinic: from hype to hope. Cell Stem Cell 24, 25\u201340 (2019).","journal-title":"Cell Stem Cell"},{"key":"2682_CR231","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1146\/annurev-pathol-012615-044438","volume":"11","author":"D Nassar","year":"2016","unstructured":"Nassar, D. & Blanpain, C. Cancer stem cells: basic concepts and therapeutic implications. Annu. Rev. Pathol. 11, 47\u201376 (2016).","journal-title":"Annu. Rev. Pathol."},{"key":"2682_CR232","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1002\/(SICI)1520-6408(1996)18:3<254::AID-DVG6>3.0.CO;2-8","volume":"18","author":"E Andermarcher","year":"1996","unstructured":"Andermarcher, E., Surani, M. A. & Gherardi, E. Co-expression of the HGF\/SF and c-met genes during early mouse embryogenesis precedes reciprocal expression in adjacent tissues during organogenesis. Dev. Genet. 18, 254\u2013266 (1996).","journal-title":"Dev. Genet."},{"key":"2682_CR233","doi-asserted-by":"publisher","first-page":"3904","DOI":"10.1002\/dvdy.21794","volume":"237","author":"AJ Latimer","year":"2008","unstructured":"Latimer, A. J. & Jessen, J. R. Hgf\/c-met expression and functional analysis during zebrafish embryogenesis. Dev. Dyn. 237, 3904\u20133915 (2008).","journal-title":"Dev. Dyn."},{"key":"2682_CR234","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1593\/tlo.13127","volume":"6","author":"P Rath","year":"2013","unstructured":"Rath, P. et al. In vivo c-Met pathway inhibition depletes human glioma xenografts of tumor-propagating stem-like cells. Transl. Oncol. 6, 104\u2013111 (2013).","journal-title":"Transl. Oncol."},{"key":"2682_CR235","doi-asserted-by":"publisher","first-page":"3828","DOI":"10.1158\/0008-5472.CAN-11-3760","volume":"72","author":"KM Joo","year":"2012","unstructured":"Joo, K. M. et al. MET signaling regulates glioblastoma stem cells. Cancer Res. 72, 3828\u20133838 (2012).","journal-title":"Cancer Res."},{"key":"2682_CR236","doi-asserted-by":"publisher","first-page":"6750","DOI":"10.3748\/wjg.v23.i37.6750","volume":"23","author":"TN Flores-Tellez","year":"2017","unstructured":"Flores-Tellez, T. N., Villa-Trevino, S. & Pina-Vazquez, C. Road to stemness in hepatocellular carcinoma. World J. Gastroenterol. 23, 6750\u20136776 (2017).","journal-title":"World J. Gastroenterol."},{"key":"2682_CR237","doi-asserted-by":"publisher","first-page":"7546","DOI":"10.1158\/0008-5472.CAN-14-0826","volume":"74","author":"S Sun","year":"2014","unstructured":"Sun, S. et al. Targeting the c-Met\/FZD8 signaling axis eliminates patient-derived cancer stem-like cells in head and neck squamous carcinomas. Cancer Res. 74, 7546\u20137559 (2014).","journal-title":"Cancer Res."},{"key":"2682_CR238","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1038\/ncb2048","volume":"12","author":"L Vermeulen","year":"2010","unstructured":"Vermeulen, L. et al. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat. Cell Biol. 12, 468\u2013476 (2010).","journal-title":"Nat. Cell Biol."},{"key":"2682_CR239","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.devcel.2009.06.016","volume":"17","author":"BT MacDonald","year":"2009","unstructured":"MacDonald, B. T., Tamai, K. & He, X. Wnt\/beta-catenin signaling: components, mechanisms, and diseases. Dev. Cell 17, 9\u201326 (2009).","journal-title":"Dev. Cell"},{"key":"2682_CR240","doi-asserted-by":"crossref","unstructured":"Arnold, L., Enders, J. & Thomas, S. M. Activated HGF-c-met axis in head and neck cancer. Cancers. 9, 169 (2017).","DOI":"10.3390\/cancers9120169"},{"key":"2682_CR241","doi-asserted-by":"publisher","first-page":"4970","DOI":"10.1158\/0008-5472.CAN-15-3541","volume":"76","author":"F Xing","year":"2016","unstructured":"Xing, F. et al. Activation of the c-met pathway mobilizes an inflammatory network in the brain microenvironment to promote brain metastasis of breast cancer. Cancer Res. 76, 4970\u20134980 (2016).","journal-title":"Cancer Res."},{"key":"2682_CR242","doi-asserted-by":"publisher","first-page":"9355","DOI":"10.1158\/0008-5472.CAN-05-1946","volume":"65","author":"Y Li","year":"2005","unstructured":"Li, Y. et al. The scatter factor\/hepatocyte growth factor: c-met pathway in human embryonal central nervous system tumor malignancy. Cancer Res. 65, 9355\u20139362 (2005).","journal-title":"Cancer Res."},{"key":"2682_CR243","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.yexcr.2018.07.041","volume":"371","author":"B Yan","year":"2018","unstructured":"Yan, B. et al. Paracrine HGF\/c-MET enhances the stem cell-like potential and glycolysis of pancreatic cancer cells via activation of YAP\/HIF-1alpha. Exp. Cell Res. 371, 63\u201371 (2018).","journal-title":"Exp. Cell Res."},{"key":"2682_CR244","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1016\/j.celrep.2016.04.019","volume":"15","author":"EY Lau","year":"2016","unstructured":"Lau, E. Y. et al. Cancer-associated fibroblasts regulate tumor-initiating cell plasticity in hepatocellular carcinoma through c-Met\/FRA1\/HEY1 signaling. Cell Rep. 15, 1175\u20131189 (2016).","journal-title":"Cell Rep."},{"key":"2682_CR245","doi-asserted-by":"crossref","unstructured":"Essex, A. et al. Replication study: Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Elife. 8, e45426 (2019).","DOI":"10.7554\/eLife.45426"},{"key":"2682_CR246","doi-asserted-by":"crossref","unstructured":"Evans, J. et al. Registered report: Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Elife. 4, e05417 (2015).","DOI":"10.7554\/eLife.07301"},{"key":"2682_CR247","unstructured":"Koike, H. et al. Macrophage subpopulation promotes skeletal muscle regeneration through HGF\/MET signaling-mediated skeletal muscle stem cell proliferation. Aging Cell e70042 (2025)."},{"key":"2682_CR248","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1186\/s10020-024-00996-4","volume":"30","author":"L Hu","year":"2024","unstructured":"Hu, L. et al. Leveraging CAR macrophages targeting c-Met for precision immunotherapy in pancreatic cancer: insights from single-cell multi-omics. Mol. Med. 30, 231 (2024).","journal-title":"Mol. Med."},{"key":"2682_CR249","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1080\/15548627.2019.1580105","volume":"15","author":"X Huang","year":"2019","unstructured":"Huang, X. et al. The HGF-MET axis coordinates liver cancer metabolism and autophagy for chemotherapeutic resistance. Autophagy 15, 1258\u20131279 (2019).","journal-title":"Autophagy"},{"key":"2682_CR250","doi-asserted-by":"publisher","first-page":"E8685","DOI":"10.1073\/pnas.1701821114","volume":"114","author":"A Jahangiri","year":"2017","unstructured":"Jahangiri, A. et al. Cross-activating c-Met\/beta1 integrin complex drives metastasis and invasive resistance in cancer. Proc. Natl. Acad. Sci. USA 114, E8685\u2013E8694 (2017).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2682_CR251","doi-asserted-by":"publisher","first-page":"i10","DOI":"10.1093\/annonc\/mdx703","volume":"29","author":"D Westover","year":"2018","unstructured":"Westover, D. et al. Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors. Ann. Oncol. 29, i10\u2013i19 (2018).","journal-title":"Ann. Oncol."},{"key":"2682_CR252","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1016\/S2213-2600(20)30154-5","volume":"8","author":"YL Wu","year":"2020","unstructured":"Wu, Y. L. et al. Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b\/2, multicentre, randomised trial. Lancet Respir. Med. 8, 1132\u20131143 (2020).","journal-title":"Lancet Respir. Med."},{"key":"2682_CR253","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1126\/science.1141478","volume":"316","author":"JA Engelman","year":"2007","unstructured":"Engelman, J. A. et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316, 1039\u20131043 (2007).","journal-title":"Science"},{"key":"2682_CR254","doi-asserted-by":"publisher","first-page":"20932","DOI":"10.1073\/pnas.0710370104","volume":"104","author":"J Bean","year":"2007","unstructured":"Bean, J. et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc. Natl. Acad. Sci. USA 104, 20932\u201320937 (2007).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2682_CR255","doi-asserted-by":"publisher","first-page":"e2400603","DOI":"10.1002\/advs.202400603","volume":"11","author":"N Liu","year":"2024","unstructured":"Liu, N. et al. Reversing MET-mediated resistance in oncogene-driven NSCLC by MET-activated Wnt condensative prodrug. Adv. Sci. 11, e2400603 (2024).","journal-title":"Adv. Sci."},{"key":"2682_CR256","doi-asserted-by":"crossref","unstructured":"Huang, M. et al. Wnt-mediated endothelial transformation into mesenchymal stem cell-like cells induces chemoresistance in glioblastoma. Sci Transl Med. 12, eaay7522 (2020).","DOI":"10.1126\/scitranslmed.aay7522"},{"key":"2682_CR257","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1016\/S2213-2600(20)30171-5","volume":"8","author":"R Rosell","year":"2020","unstructured":"Rosell, R., Chaib, I. & Santarpia, M. Targeting MET amplification in EGFR-mutant non-small-cell lung cancer. Lancet Respir. Med. 8, 1068\u20131070 (2020).","journal-title":"Lancet Respir. Med."},{"key":"2682_CR258","doi-asserted-by":"publisher","first-page":"8519","DOI":"10.1038\/sj.onc.1206968","volume":"22","author":"DM Aebersold","year":"2003","unstructured":"Aebersold, D. M. et al. Prevalence and clinical impact of Met Y1253D-activating point mutation in radiotherapy-treated squamous cell cancer of the oropharynx. Oncogene 22, 8519\u20138523 (2003).","journal-title":"Oncogene"},{"key":"2682_CR259","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.ijrobp.2022.12.029","volume":"116","author":"B Wang","year":"2023","unstructured":"Wang, B. et al. Cancer-associated fibroblasts promote radioresistance of breast cancer cells via the HGF\/c-Met signaling pathway. Int. J. Radiat. Oncol. Biol. Phys. 116, 640\u2013654 (2023).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"2682_CR260","first-page":"7926","volume":"63","author":"K Jankowski","year":"2003","unstructured":"Jankowski, K. et al. Both hepatocyte growth factor (HGF) and stromal-derived factor-1 regulate the metastatic behavior of human rhabdomyosarcoma cells, but only HGF enhances their resistance to radiochemotherapy. Cancer Res. 63, 7926\u20137935 (2003).","journal-title":"Cancer Res."},{"key":"2682_CR261","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.prp.2016.05.006","volume":"212","author":"JS Pyo","year":"2016","unstructured":"Pyo, J. S., Kang, G., Cho, W. J. & Choi, S. B. Clinicopathological significance and concordance analysis of c-MET immunohistochemistry in non-small cell lung cancers: a meta-analysis. Pathol. Res. Pract. 212, 710\u2013716 (2016).","journal-title":"Pathol. Res. Pract."},{"key":"2682_CR262","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1200\/JCO.2015.63.4600","volume":"34","author":"MM Awad","year":"2016","unstructured":"Awad, M. M. et al. MET exon 14 mutations in non-small-cell lung cancer are associated with advanced age and stage-dependent MET genomic amplification and c-met overexpression. J. Clin. Oncol. 34, 721\u2013730 (2016).","journal-title":"J. Clin. Oncol."},{"key":"2682_CR263","doi-asserted-by":"publisher","first-page":"e171","DOI":"10.1016\/j.cllc.2018.11.007","volume":"20","author":"Z Song","year":"2019","unstructured":"Song, Z. et al. De novo MET amplification in chinese patients with non-small-cell lung cancer and treatment efficacy with crizotinib: a multicenter retrospective study. Clin. Lung Cancer 20, e171\u2013e176 (2019).","journal-title":"Clin. Lung Cancer"},{"key":"2682_CR264","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.lungcan.2018.07.006","volume":"123","author":"HG Vuong","year":"2018","unstructured":"Vuong, H. G. et al. Clinicopathological implications of MET exon 14 mutations in non-small cell lung cancer - a systematic review and meta-analysis. Lung Cancer 123, 76\u201382 (2018).","journal-title":"Lung Cancer"},{"key":"2682_CR265","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.7150\/jca.24980","volume":"9","author":"JH Kim","year":"2018","unstructured":"Kim, J. H., Kim, H. S. & Kim, B. J. Prognostic value of MET copy number gain in non-small-cell lung cancer: an updated meta-analysis. J. Cancer 9, 1836\u20131845 (2018).","journal-title":"J. Cancer"},{"key":"2682_CR266","doi-asserted-by":"crossref","unstructured":"Fois, S. S. et al. Molecular epidemiology of the main druggable genetic alterations in non-small cell lung cancer. Int. J. Mol. Sci. 22, 612 (2021).","DOI":"10.3390\/ijms22020612"},{"key":"2682_CR267","doi-asserted-by":"crossref","unstructured":"Spitaleri, G. et al. MET in non-small-cell lung cancer (NSCLC): cross \u2018a long and winding road\u2019 looking for a target. Cancers 15, 4779 (2023).","DOI":"10.3390\/cancers15194779"},{"key":"2682_CR268","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1038\/bjc.2013.31","volume":"108","author":"F Zagouri","year":"2013","unstructured":"Zagouri, F. et al. High MET expression is an adverse prognostic factor in patients with triple-negative breast cancer. Br. J. Cancer 108, 1100\u20131105 (2013).","journal-title":"Br. J. Cancer"},{"key":"2682_CR269","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s13000-015-0296-y","volume":"10","author":"S Yan","year":"2015","unstructured":"Yan, S., Jiao, X., Zou, H. & Li, K. Prognostic significance of c-Met in breast cancer: a meta-analysis of 6010 cases. Diagn. Pathol. 10, 62 (2015).","journal-title":"Diagn. Pathol."},{"key":"2682_CR270","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-015-0547-6","volume":"17","author":"CM Ho-Yen","year":"2015","unstructured":"Ho-Yen, C. M., Jones, J. L. & Kermorgant, S. The clinical and functional significance of c-Met in breast cancer: a review. Breast Cancer Res. 17, 52 (2015).","journal-title":"Breast Cancer Res."},{"key":"2682_CR271","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.breast.2016.04.016","volume":"28","author":"F Wang","year":"2016","unstructured":"Wang, F. et al. Predictive role of the overexpression for CXCR4, C-Met, and VEGF-C among breast cancer patients: a meta-analysis. Breast 28, 45\u201353 (2016).","journal-title":"Breast"},{"key":"2682_CR272","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.1158\/1078-0432.CCR-03-0462","volume":"10","author":"MB Resnick","year":"2004","unstructured":"Resnick, M. B. et al. Epidermal growth factor receptor, c-MET, beta-catenin, and p53 expression as prognostic indicators in stage II colon cancer: a tissue microarray study. Clin. Cancer Res. 10, 3069\u20133075 (2004).","journal-title":"Clin. Cancer Res."},{"key":"2682_CR273","doi-asserted-by":"publisher","first-page":"3814","DOI":"10.1158\/1078-0432.CCR-08-0180","volume":"14","author":"F Ginty","year":"2008","unstructured":"Ginty, F. et al. The relative distribution of membranous and cytoplasmic met is a prognostic indicator in stage I and II colon cancer. Clin. Cancer Res. 14, 3814\u20133822 (2008).","journal-title":"Clin. Cancer Res."},{"key":"2682_CR274","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1007\/s10350-008-9297-1","volume":"51","author":"CT Lee","year":"2008","unstructured":"Lee, C. T. et al. The prognostic significance of RON and MET receptor coexpression in patients with colorectal cancer. Dis. Colon Rectum 51, 1268\u20131274 (2008).","journal-title":"Dis. Colon Rectum"},{"key":"2682_CR275","first-page":"4807","volume":"29","author":"AT De Oliveira","year":"2009","unstructured":"De Oliveira, A. T. et al. MET is highly expressed in advanced stages of colorectal cancer and indicates worse prognosis and mortality. Anticancer Res. 29, 4807\u20134811 (2009).","journal-title":"Anticancer Res."},{"key":"2682_CR276","doi-asserted-by":"publisher","first-page":"3706","DOI":"10.3748\/wjg.v21.i12.3706","volume":"21","author":"Y Liu","year":"2015","unstructured":"Liu, Y., Yu, X. F., Zou, J. & Luo, Z. H. Prognostic value of c-Met in colorectal cancer: a meta-analysis. World J. Gastroenterol. 21, 3706\u20133710 (2015).","journal-title":"World J. Gastroenterol."},{"key":"2682_CR277","first-page":"165","volume":"17","author":"SJ Lee","year":"2018","unstructured":"Lee, S. J. et al. c-MET overexpression in colorectal cancer: a poor prognostic factor for survival. Clin. Colorectal Cancer 17, 165\u2013169 (2018).","journal-title":"Clin. Colorectal Cancer"},{"key":"2682_CR278","first-page":"294","volume":"40","author":"KH Huang","year":"2018","unstructured":"Huang, K. H. et al. Correlation between HGF\/c-Met and Notch1 signaling pathways in human gastric cancer cells. Oncol. Rep. 40, 294\u2013302 (2018).","journal-title":"Oncol. Rep."},{"key":"2682_CR279","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1097\/PAI.0000000000000448","volume":"26","author":"J Choi","year":"2018","unstructured":"Choi, J. et al. Evaluation of intratumoral and intertumoral heterogeneity of MET protein expression in gastric cancer. Appl. Immunohistochem. Mol. Morphol. 26, 445\u2013453 (2018).","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"2682_CR280","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1002\/cncr.30437","volume":"123","author":"DV Catenacci","year":"2017","unstructured":"Catenacci, D. V. et al. MET tyrosine kinase receptor expression and amplification as prognostic biomarkers of survival in gastroesophageal adenocarcinoma. Cancer 123, 1061\u20131070 (2017).","journal-title":"Cancer"},{"key":"2682_CR281","doi-asserted-by":"publisher","first-page":"97","DOI":"10.23736\/S0031-0808.16.03228-6","volume":"59","author":"JL Ren","year":"2017","unstructured":"Ren, J. L. et al. C-Met as a potential novel prognostic marker in squamous cell carcinoma and adenocarcinoma of esophagus: evidence from a meta-analysis. Panminerva Med. 59, 97\u2013106 (2017).","journal-title":"Panminerva Med."},{"key":"2682_CR282","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.oraloncology.2017.09.009","volume":"74","author":"P Szturz","year":"2017","unstructured":"Szturz, P. et al. Prognostic value of c-MET in head and neck cancer: a systematic review and meta-analysis of aggregate data. Oral. Oncol. 74, 68\u201376 (2017).","journal-title":"Oral. Oncol."},{"key":"2682_CR283","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-28672-8","volume":"8","author":"V Vsiansky","year":"2018","unstructured":"Vsiansky, V., Gumulec, J., Raudenska, M. & Masarik, M. Prognostic role of c-Met in head and neck squamous cell cancer tissues: a meta-analysis. Sci. Rep. 8, 10370 (2018).","journal-title":"Sci. Rep."},{"key":"2682_CR284","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1159\/000519867","volume":"11","author":"L Rimassa","year":"2022","unstructured":"Rimassa, L. et al. Outcomes based on plasma biomarkers for the phase 3 celestial trial of cabozantinib versus placebo in advanced hepatocellular carcinoma. Liver Cancer 11, 38\u201347 (2022).","journal-title":"Liver Cancer"},{"key":"2682_CR285","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1002\/med.21738","volume":"41","author":"J Yu","year":"2021","unstructured":"Yu, J., Chen, G. G. & Lai, P. B. S. Targeting hepatocyte growth factor\/c-mesenchymal-epithelial transition factor axis in hepatocellular carcinoma: Rationale and therapeutic strategies. Med. Res. Rev. 41, 507\u2013524 (2021).","journal-title":"Med. Res. Rev."},{"key":"2682_CR286","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1093\/annonc\/mds463","volume":"24","author":"GT Gibney","year":"2013","unstructured":"Gibney, G. T. et al. c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma. Ann. Oncol. 24, 343\u2013349 (2013).","journal-title":"Ann. Oncol."},{"key":"2682_CR287","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.humpath.2005.10.012","volume":"37","author":"HW Tsai","year":"2006","unstructured":"Tsai, H. W. et al. The significance of prohibitin and c-Met\/hepatocyte growth factor receptor in the progression of cervical adenocarcinoma. Hum. Pathol. 37, 198\u2013204 (2006).","journal-title":"Hum. Pathol."},{"key":"2682_CR288","doi-asserted-by":"publisher","first-page":"6594016","DOI":"10.1155\/2016\/6594016","volume":"2016","author":"J Peng","year":"2016","unstructured":"Peng, J. et al. Diagnosis and prognostic significance of c-Met in cervical cancer: a meta-analysis. Dis. Markers 2016, 6594016 (2016).","journal-title":"Dis. Markers"},{"key":"2682_CR289","doi-asserted-by":"publisher","first-page":"4490","DOI":"10.1002\/jcp.26232","volume":"233","author":"N Boromand","year":"2018","unstructured":"Boromand, N. et al. Clinical and prognostic value of the C-Met\/HGF signaling pathway in cervical cancer. J. Cell Physiol. 233, 4490\u20134496 (2018).","journal-title":"J. Cell Physiol."},{"key":"2682_CR290","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s10120-015-0471-6","volume":"19","author":"N Fuse","year":"2016","unstructured":"Fuse, N. et al. Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients. Gastric Cancer 19, 183\u2013191 (2016).","journal-title":"Gastric Cancer"},{"key":"2682_CR291","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-014-1001-3","volume":"15","author":"Y Xu","year":"2015","unstructured":"Xu, Y. et al. Expression and clinical significance of c-Met in advanced esophageal squamous cell carcinoma. BMC Cancer 15, 6 (2015).","journal-title":"BMC Cancer"},{"key":"2682_CR292","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/bjc.2012.237","volume":"107","author":"HE Lee","year":"2012","unstructured":"Lee, H. E. et al. MET in gastric carcinomas: comparison between protein expression and gene copy number and impact on clinical outcome. Br. J. Cancer 107, 325\u2013333 (2012).","journal-title":"Br. J. Cancer"},{"key":"2682_CR293","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.jtho.2022.10.015","volume":"18","author":"J Remon","year":"2023","unstructured":"Remon, J. et al. MET alterations in NSCLC-current perspectives and future challenges. J. Thorac. Oncol. 18, 419\u2013435 (2023).","journal-title":"J. Thorac. Oncol."},{"key":"2682_CR294","doi-asserted-by":"crossref","unstructured":"Spagnolo, C. C. et al. Targeting MET in non-small cell lung cancer (NSCLC): a new old story? Int. J. Mol. Sci. 24, 10119 (2023).","DOI":"10.3390\/ijms241210119"},{"key":"2682_CR295","first-page":"484","volume":"21","author":"Y Zhang","year":"2024","unstructured":"Zhang, Y., Shen, L. & Peng, Z. Advances in MET tyrosine kinase inhibitors in gastric cancer. Cancer Biol. Med. 21, 484\u2013498 (2024).","journal-title":"Cancer Biol. Med."},{"key":"2682_CR296","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-01274-7","volume":"19","author":"Y Jin","year":"2020","unstructured":"Jin, Y. et al. The predicting role of circulating tumor DNA landscape in gastric cancer patients treated with immune checkpoint inhibitors. Mol. Cancer 19, 154 (2020).","journal-title":"Mol. Cancer"},{"key":"2682_CR297","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/modpathol.2012.150","volume":"26","author":"A Voutsina","year":"2013","unstructured":"Voutsina, A. et al. Combined analysis of KRAS and PIK3CA mutations, MET and PTEN expression in primary tumors and corresponding metastases in colorectal cancer. Mod. Pathol. 26, 302\u2013313 (2013).","journal-title":"Mod. Pathol."},{"key":"2682_CR298","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-015-1662-6","volume":"15","author":"J Al-Maghrabi","year":"2015","unstructured":"Al-Maghrabi, J. et al. c-MET immunostaining in colorectal carcinoma is associated with local disease recurrence. BMC Cancer 15, 676 (2015).","journal-title":"BMC Cancer"},{"key":"2682_CR299","doi-asserted-by":"publisher","first-page":"113153","DOI":"10.1016\/j.intimp.2024.113153","volume":"142","author":"X Wan","year":"2024","unstructured":"Wan, X., Li, Z. & Zhou, L. c-MET is an important marker for acid-driven metastasis and anti-immune in colorectal cancer. Int Immunopharmacol. 142, 113153 (2024).","journal-title":"Int Immunopharmacol."},{"key":"2682_CR300","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1093\/ejcts\/ezv323","volume":"49","author":"T Schweiger","year":"2016","unstructured":"Schweiger, T. et al. Clinical impact of c-MET expression and mutational status in patients with colorectal cancer lung metastases. Eur. J. Cardiothorac. Surg. 49, 1103\u20131111 (2016).","journal-title":"Eur. J. Cardiothorac. Surg."},{"key":"2682_CR301","first-page":"148","volume":"3","author":"HN Mo","year":"2017","unstructured":"Mo, H. N. & Liu, P. Targeting MET in cancer therapy. Chronic Dis. Transl. Med. 3, 148\u2013153 (2017).","journal-title":"Chronic Dis. Transl. Med."},{"key":"2682_CR302","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.phrs.2015.10.021","volume":"103","author":"R Roskoski Jr.","year":"2016","unstructured":"Roskoski, R. Jr. Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes. Pharm. Res. 103, 26\u201348 (2016).","journal-title":"Pharm. Res."},{"key":"2682_CR303","doi-asserted-by":"publisher","DOI":"10.1038\/emm.2017.17","volume":"49","author":"KH Kim","year":"2017","unstructured":"Kim, K. H. & Kim, H. Progress of antibody-based inhibitors of the HGF-cMET axis in cancer therapy. Exp. Mol. Med. 49, e307 (2017).","journal-title":"Exp. Mol. Med."},{"key":"2682_CR304","unstructured":"Zhu, Z. et al. Membrane-bounded intracellular E3 ubiquitin ligase-targeting chimeras (MembTACs) for targeted membrane protein degradation. Angew. Chem. Int. Ed. Engl. e202501857, (2025)."},{"key":"2682_CR305","doi-asserted-by":"publisher","first-page":"103","DOI":"10.7150\/thno.99588","volume":"15","author":"X Fu","year":"2025","unstructured":"Fu, X. et al. Development of dual aptamers-functionalized c-MET PROTAC degraders for targeted therapy of osteosarcoma. Theranostics 15, 103\u2013121 (2025).","journal-title":"Theranostics"},{"key":"2682_CR306","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s10585-011-9447-z","volume":"29","author":"Y Dai","year":"2012","unstructured":"Dai, Y., Bae, K., Pampo, C. & Siemann, D. W. Impact of the small molecule Met inhibitor BMS-777607 on the metastatic process in a rodent tumor model with constitutive c-Met activation. Clin. Exp. Metastasis 29, 253\u2013261 (2012).","journal-title":"Clin. Exp. Metastasis"},{"key":"2682_CR307","doi-asserted-by":"publisher","first-page":"112470","DOI":"10.1016\/j.ejmech.2020.112470","volume":"200","author":"X Nan","year":"2020","unstructured":"Nan, X. et al. Design, synthesis and biological evaluation of novel N-sulfonylamidine-based derivatives as c-Met inhibitors via Cu-catalyzed three-component reaction. Eur. J. Med. Chem. 200, 112470 (2020).","journal-title":"Eur. J. Med. Chem."},{"key":"2682_CR308","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/j.ejmech.2017.08.044","volume":"143","author":"PK Parikh","year":"2018","unstructured":"Parikh, P. K. & Ghate, M. D. Recent advances in the discovery of small molecule c-Met Kinase inhibitors. Eur. J. Med. Chem. 143, 1103\u20131138 (2018).","journal-title":"Eur. J. Med. Chem."},{"key":"2682_CR309","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.jmgm.2017.04.004","volume":"75","author":"MJ Li","year":"2017","unstructured":"Li, M. J. et al. Development of efficient docking strategies and structure-activity relationship study of the c-Met type II inhibitors. J. Mol. Graph Model 75, 241\u2013249 (2017).","journal-title":"J. Mol. Graph Model"},{"key":"2682_CR310","doi-asserted-by":"publisher","first-page":"105304","DOI":"10.1016\/j.bioorg.2021.105304","volume":"116","author":"MH El-Wakil","year":"2021","unstructured":"El-Wakil, M. H. & Teleb, M. Transforming type II to type I c-Met kinase inhibitors via combined scaffold hopping and structure-guided synthesis of new series of 1,3,4-thiadiazolo[2,3-c]-1,2,4-triazin-4-one derivatives. Bioorg. Chem. 116, 105304 (2021).","journal-title":"Bioorg. Chem."},{"key":"2682_CR311","doi-asserted-by":"publisher","first-page":"2801","DOI":"10.1016\/j.bmc.2019.05.007","volume":"27","author":"X Nan","year":"2019","unstructured":"Nan, X. et al. Design, synthesis and evaluation of sulfonylurea-containing 4-phenoxyquinolines as highly selective c-Met kinase inhibitors. Bioorg. Med. Chem. 27, 2801\u20132812 (2019).","journal-title":"Bioorg. Med. Chem."},{"key":"2682_CR312","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1007\/s00277-017-2980-3","volume":"96","author":"M Baljevic","year":"2017","unstructured":"Baljevic, M. et al. Phase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed\/refractory multiple myeloma. Ann. Hematol. 96, 977\u2013985 (2017).","journal-title":"Ann. Hematol."},{"key":"2682_CR313","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1158\/0008-5472.CAN-09-2541","volume":"70","author":"BS Pan","year":"2010","unstructured":"Pan, B. S. et al. MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 70, 1524\u20131533 (2010).","journal-title":"Cancer Res."},{"key":"2682_CR314","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1517\/13543784.2014.949339","volume":"23","author":"E Rota Caremoli","year":"2014","unstructured":"Rota Caremoli, E. & Labianca, R. Tivantinib: critical review with a focus on hepatocellular carcinoma. Expert Opin. Investig. Drugs 23, 1563\u20131574 (2014).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"2682_CR315","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1080\/13543776.2022.2008356","volume":"32","author":"C Chu","year":"2022","unstructured":"Chu, C., Rao, Z., Pan, Q. & Zhu, W. An updated patent review of small-molecule c-Met kinase inhibitors (2018-present). Expert Opin. Ther. Pat. 32, 279\u2013298 (2022).","journal-title":"Expert Opin. Ther. Pat."},{"key":"2682_CR316","doi-asserted-by":"publisher","first-page":"6342","DOI":"10.1021\/jm2007613","volume":"54","author":"JJ Cui","year":"2011","unstructured":"Cui, J. J. et al. Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J. Med. Chem. 54, 6342\u20136363 (2011).","journal-title":"J. Med. Chem."},{"key":"2682_CR317","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s40264-018-0780-x","volume":"42","author":"A Puccini","year":"2019","unstructured":"Puccini, A. et al. Safety and tolerability of c-MET inhibitors in cancer. Drug Saf. 42, 211\u2013233 (2019).","journal-title":"Drug Saf."},{"key":"2682_CR318","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41591-019-0716-8","volume":"26","author":"A Drilon","year":"2020","unstructured":"Drilon, A. et al. Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration. Nat. Med. 26, 47\u201351 (2020).","journal-title":"Nat. Med."},{"key":"2682_CR319","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1093\/annonc\/mdz407","volume":"30","author":"D Moro-Sibilot","year":"2019","unstructured":"Moro-Sibilot, D. et al. Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSe phase II trial. Ann. Oncol. 30, 1985\u20131991 (2019).","journal-title":"Ann. Oncol."},{"key":"2682_CR320","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1016\/j.jtho.2021.02.010","volume":"16","author":"DR Camidge","year":"2021","unstructured":"Camidge, D. R. et al. Crizotinib in patients with MET-amplified NSCLC. J. Thorac. Oncol. 16, 1017\u20131029 (2021).","journal-title":"J. Thorac. Oncol."},{"key":"2682_CR321","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.ejca.2017.10.014","volume":"87","author":"P Schoffski","year":"2017","unstructured":"Schoffski, P. et al. Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial. Eur. J. Cancer 87, 147\u2013163 (2017).","journal-title":"Eur. J. Cancer"},{"key":"2682_CR322","doi-asserted-by":"publisher","first-page":"7127","DOI":"10.1158\/1078-0432.CCR-11-1157","volume":"17","author":"X Liu","year":"2011","unstructured":"Liu, X. et al. A novel kinase inhibitor, INCB28060, blocks c-MET-dependent signaling, neoplastic activities, and cross-talk with EGFR and HER-3. Clin. Cancer Res. 17, 7127\u20137138 (2011).","journal-title":"Clin. Cancer Res."},{"key":"2682_CR323","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.canlet.2021.04.029","volume":"512","author":"S Mori","year":"2021","unstructured":"Mori, S. et al. Inhibition of c-MET reverses radiation-induced malignant potential in pancreatic cancer. Cancer Lett. 512, 51\u201359 (2021).","journal-title":"Cancer Lett."},{"key":"2682_CR324","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1111\/cas.14254","volume":"111","author":"YJ Bang","year":"2020","unstructured":"Bang, Y. J. et al. Phase 1 study of capmatinib in MET-positive solid tumor patients: dose escalation and expansion of selected cohorts. Cancer Sci. 111, 536\u2013547 (2020).","journal-title":"Cancer Sci."},{"key":"2682_CR325","doi-asserted-by":"publisher","first-page":"3164","DOI":"10.1158\/1078-0432.CCR-18-2814","volume":"25","author":"S Baltschukat","year":"2019","unstructured":"Baltschukat, S. et al. Capmatinib (INC280) is active against models of non-small cell lung cancer and other cancer types with defined mechanisms of MET activation. Clin. Cancer Res. 25, 3164\u20133175 (2019).","journal-title":"Clin. Cancer Res."},{"key":"2682_CR326","doi-asserted-by":"publisher","first-page":"3101","DOI":"10.1200\/JCO.2018.77.7326","volume":"36","author":"YL Wu","year":"2018","unstructured":"Wu, Y. L. et al. Phase Ib\/II study of capmatinib (INC280) plus gefitinib after failure of epidermal growth factor receptor (EGFR) inhibitor therapy in patients with EGFR-mutated, MET factor-dysregulated non-small-cell lung cancer. J. Clin. Oncol. 36, 3101\u20133109 (2018).","journal-title":"J. Clin. Oncol."},{"key":"2682_CR327","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1056\/NEJMoa2002787","volume":"383","author":"J Wolf","year":"2020","unstructured":"Wolf, J. et al. Capmatinib in MET Exon 14-mutated or MET-amplified non-small-cell lung cancer. N. Engl. J. Med. 383, 944\u2013957 (2020).","journal-title":"N. Engl. J. Med."},{"key":"2682_CR328","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.annonc.2020.03.293","volume":"31","author":"M Schuler","year":"2020","unstructured":"Schuler, M. et al. Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer: clinical and biomarker results from a phase I trial. Ann. Oncol. 31, 789\u2013797 (2020).","journal-title":"Ann. Oncol."},{"key":"2682_CR329","doi-asserted-by":"crossref","unstructured":"Hsu, R., Benjamin, D. J. & Nagasaka, M. The development and role of capmatinib in the treatment of MET-dysregulated non-small cell lung cancer\u2014a narrative review. Cancers 15, 3561 (2023).","DOI":"10.3390\/cancers15143561"},{"key":"2682_CR330","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.jtho.2021.01.1605","volume":"16","author":"I Dagogo-Jack","year":"2021","unstructured":"Dagogo-Jack, I. et al. A phase 2 study of capmatinib in patients with MET-altered lung cancer previously treated with a MET inhibitor. J. Thorac. Oncol. 16, 850\u2013859 (2021).","journal-title":"J. Thorac. Oncol."},{"key":"2682_CR331","first-page":"100533","volume":"4","author":"K Wang","year":"2023","unstructured":"Wang, K. et al. Brief report: clinical response, toxicity, and resistance mechanisms to osimertinib plus MET inhibitors in patients with EGFR-mutant MET-amplified NSCLC. JTO Clin. Res. Rep. 4, 100533 (2023).","journal-title":"JTO Clin. Res. Rep."},{"key":"2682_CR332","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/S1470-2045(24)00441-8","volume":"25","author":"J Wolf","year":"2024","unstructured":"Wolf, J. et al. Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trial. Lancet Oncol. 25, 1357\u20131370 (2024).","journal-title":"Lancet Oncol."},{"key":"2682_CR333","doi-asserted-by":"publisher","first-page":"7577","DOI":"10.1021\/jm500510f","volume":"57","author":"H Jia","year":"2014","unstructured":"Jia, H. et al. Discovery of (S)-1-(1-(Imidazo[1,2-a]pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazine (volitinib) as a highly potent and selective mesenchymal-epithelial transition factor (c-Met) inhibitor in clinical development for treatment of cancer. J. Med. Chem. 57, 7577\u20137589 (2014).","journal-title":"J. Med. Chem."},{"key":"2682_CR334","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/S1470-2045(19)30785-5","volume":"21","author":"LV Sequist","year":"2020","unstructured":"Sequist, L. V. et al. Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study. Lancet Oncol. 21, 373\u2013386 (2020).","journal-title":"Lancet Oncol."},{"key":"2682_CR335","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s10637-020-01010-4","volume":"39","author":"JJ Yang","year":"2021","unstructured":"Yang, J. J. et al. A phase Ib study of the highly selective MET-TKI savolitinib plus gefitinib in patients with EGFR-mutated, MET-amplified advanced non-small-cell lung cancer. Invest. New Drugs 39, 477\u2013487 (2021).","journal-title":"Invest. New Drugs"},{"key":"2682_CR336","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1016\/S2213-2600(21)00084-9","volume":"9","author":"S Lu","year":"2021","unstructured":"Lu, S. et al. Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study. Lancet Respir. Med. 9, 1154\u20131164 (2021).","journal-title":"Lancet Respir. Med."},{"key":"2682_CR337","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1001\/jamaoncol.2020.2218","volume":"6","author":"TK Choueiri","year":"2020","unstructured":"Choueiri, T. K. et al. Efficacy of savolitinib vs sunitinib in patients with MET-driven papillary renal cell carcinoma: the SAVOIR phase 3 randomized clinical trial. JAMA Oncol. 6, 1247\u20131255 (2020).","journal-title":"JAMA Oncol."},{"key":"2682_CR338","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1200\/JCO.2017.72.2967","volume":"35","author":"TK Choueiri","year":"2017","unstructured":"Choueiri, T. K. et al. Biomarker-based phase II trial of savolitinib in patients with advanced papillary renal cell cancer. J. Clin. Oncol. 35, 2993\u20133001 (2017).","journal-title":"J. Clin. Oncol."},{"key":"2682_CR339","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1038\/bjc.2017.354","volume":"117","author":"C Dantas-Barbosa","year":"2017","unstructured":"Dantas-Barbosa, C. et al. Expression and role of TYRO3 and AXL as potential therapeutical targets in leiomyosarcoma. Br. J. Cancer 117, 1787\u20131797 (2017).","journal-title":"Br. J. Cancer"},{"key":"2682_CR340","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s10549-016-3812-1","volume":"157","author":"D Rayson","year":"2016","unstructured":"Rayson, D. et al. Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer. Breast Cancer Res. Treat. 157, 109\u2013116 (2016).","journal-title":"Breast Cancer Res. Treat."},{"key":"2682_CR341","doi-asserted-by":"publisher","first-page":"3507","DOI":"10.1158\/1078-0432.CCR-10-0574","volume":"16","author":"JP Eder","year":"2010","unstructured":"Eder, J. P. et al. A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2. Clin. Cancer Res. 16, 3507\u20133516 (2010).","journal-title":"Clin. Cancer Res."},{"key":"2682_CR342","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1158\/1078-0432.CCR-16-1789","volume":"23","author":"TCC Yau","year":"2017","unstructured":"Yau, T. C. C. et al. A phase I\/II multicenter study of single-agent foretinib as first-line therapy in patients with advanced hepatocellular carcinoma. Clin. Cancer Res. 23, 2405\u20132413 (2017).","journal-title":"Clin. Cancer Res."},{"key":"2682_CR343","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1200\/JCO.2012.43.3383","volume":"31","author":"TK Choueiri","year":"2013","unstructured":"Choueiri, T. K. et al. Phase II and biomarker study of the dual MET\/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J. Clin. Oncol. 31, 181\u2013186 (2013).","journal-title":"J. Clin. Oncol."},{"key":"2682_CR344","doi-asserted-by":"publisher","first-page":"2941","DOI":"10.1158\/1078-0432.CCR-12-3247","volume":"19","author":"F Bladt","year":"2013","unstructured":"Bladt, F. et al. EMD 1214063 and EMD 1204831 constitute a new class of potent and highly selective c-Met inhibitors. Clin. Cancer Res. 19, 2941\u20132951 (2013).","journal-title":"Clin. Cancer Res."},{"key":"2682_CR345","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1002\/hep.24450","volume":"54","author":"H You","year":"2011","unstructured":"You, H. et al. c-Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinoma. Hepatology 54, 879\u2013889 (2011).","journal-title":"Hepatology"},{"key":"2682_CR346","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.3390\/cancers6031736","volume":"6","author":"F Bladt","year":"2014","unstructured":"Bladt, F. et al. The c-Met inhibitor MSC2156119J effectively inhibits tumor growth in liver cancer models. Cancers 6, 1736\u20131752 (2014).","journal-title":"Cancers"},{"key":"2682_CR347","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1158\/1078-0432.CCR-19-2860","volume":"26","author":"GS Falchook","year":"2020","unstructured":"Falchook, G. S. et al. First-in-man phase I trial of the selective MET inhibitor tepotinib in patients with advanced solid tumors. Clin. Cancer Res. 26, 1237\u20131246 (2020).","journal-title":"Clin. Cancer Res."},{"key":"2682_CR348","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/s41416-021-01334-9","volume":"125","author":"T Decaens","year":"2021","unstructured":"Decaens, T. et al. Phase 1b\/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression. Br. J. Cancer 125, 190\u2013199 (2021).","journal-title":"Br. J. Cancer"},{"key":"2682_CR349","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1056\/NEJMoa2004407","volume":"383","author":"PK Paik","year":"2020","unstructured":"Paik, P. K. et al. Tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations. N. Engl. J. Med. 383, 931\u2013943 (2020).","journal-title":"N. Engl. J. Med."},{"key":"2682_CR350","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41416-021-01380-3","volume":"125","author":"BY Ryoo","year":"2021","unstructured":"Ryoo, B. Y. et al. Randomised Phase 1b\/2 trial of tepotinib vs sorafenib in Asian patients with advanced hepatocellular carcinoma with MET overexpression. Br. J. Cancer 125, 200\u2013208 (2021).","journal-title":"Br. J. Cancer"},{"key":"2682_CR351","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/S1470-2045(24)00270-5","volume":"25","author":"YL Wu","year":"2024","unstructured":"Wu, Y. L. et al. Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial. Lancet Oncol. 25, 989\u20131002 (2024).","journal-title":"Lancet Oncol."},{"key":"2682_CR352","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1001\/jamaoncol.2023.1962","volume":"9","author":"J Mazieres","year":"2023","unstructured":"Mazieres, J. et al. Tepotinib treatment in patients with MET exon 14-skipping non-small cell lung cancer: long-term follow-up of the VISION phase 2 nonrandomized clinical trial. JAMA Oncol. 9, 1260\u20131266 (2023).","journal-title":"JAMA Oncol."},{"key":"2682_CR353","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jchromb.2017.10.017","volume":"1068-1069","author":"X Cui","year":"2017","unstructured":"Cui, X. et al. Simultaneous determination of a novel c-Met\/AXL dual-target small-molecule inhibitor BPI-9016M and its metabolites in human plasma by liquid chromatography-tandem mass spectrometry: Application in a pharmacokinetic study in Chinese advanced solid tumor patients. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 1068-1069, 33\u201340 (2017).","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"2682_CR354","doi-asserted-by":"publisher","first-page":"5890","DOI":"10.7150\/thno.27667","volume":"8","author":"P Zhang","year":"2018","unstructured":"Zhang, P. et al. BPI-9016M, a c-Met inhibitor, suppresses tumor cell growth, migration and invasion of lung adenocarcinoma via miR203-DKK1. Theranostics 8, 5890\u20135902 (2018).","journal-title":"Theranostics"},{"key":"2682_CR355","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13045-019-0834-2","volume":"13","author":"X Hu","year":"2020","unstructured":"Hu, X. et al. First-in-human phase I study of BPI-9016M, a dual MET\/Axl inhibitor, in patients with non-small cell lung cancer. J. Hematol. Oncol. 13, 6 (2020).","journal-title":"J. Hematol. Oncol."},{"key":"2682_CR356","first-page":"7345","volume":"63","author":"JG Christensen","year":"2003","unstructured":"Christensen, J. G. et al. A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Res. 63, 7345\u20137355 (2003).","journal-title":"Cancer Res."},{"key":"2682_CR357","doi-asserted-by":"crossref","unstructured":"Yadav, A. K., Wang, S., Shin, Y. M. & Jang, B. C. PHA-665752\u2019s antigrowth and proapoptotic effects on HSC-3 human oral cancer cells. Int. J. Mol. Sci. 25, 2871 (2024).","DOI":"10.3390\/ijms25052871"},{"key":"2682_CR358","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.1073\/pnas.0508776103","volume":"103","author":"GA Smolen","year":"2006","unstructured":"Smolen, G. A. et al. Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc. Natl. Acad. Sci. USA 103, 2316\u20132321 (2006).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2682_CR359","doi-asserted-by":"publisher","first-page":"278","DOI":"10.2174\/1568009617666170330112841","volume":"18","author":"YT Jia","year":"2018","unstructured":"Jia, Y. T. et al. Effects of PHA-665752 and cetuximab combination treatment on in vitro and murine xenograft growth of human colorectal cancer cells with KRAS or BRAF mutations. Curr. Cancer Drug Targets 18, 278\u2013286 (2018).","journal-title":"Curr. Cancer Drug Targets"},{"key":"2682_CR360","doi-asserted-by":"crossref","unstructured":"Kim, N. A. et al. New preclinical development of a c-Met inhibitor and its combined anti-tumor effect in c-met-amplified NSCLC. Pharmaceutics. 12, 121 (2020).","DOI":"10.3390\/pharmaceutics12020121"},{"key":"2682_CR361","doi-asserted-by":"crossref","unstructured":"Ravi, M. et al. Solubility determination of c-Met inhibitor in solvent mixtures and mathematical modeling to develop nanosuspension formulation. Molecules. 26, 390 (2021).","DOI":"10.3390\/molecules26020390"},{"key":"2682_CR362","doi-asserted-by":"publisher","first-page":"176","DOI":"10.2174\/187231208785425818","volume":"2","author":"J Sahi","year":"2008","unstructured":"Sahi, J., Khan, K. K. & Black, C. B. Aldehyde oxidase activity and inhibition in hepatocytes and cytosolic fractions from mouse, rat, monkey and human. Drug Metab. Lett. 2, 176\u2013183 (2008).","journal-title":"Drug Metab. Lett."},{"key":"2682_CR363","doi-asserted-by":"crossref","unstructured":"Kim, J. et al. Therapeutic efficacy of ABN401, a highly potent and selective MET inhibitor, based on diagnostic biomarker test in MET-addicted cancer. Cancers 12, 1575 (2020).","DOI":"10.3390\/cancers12061575"},{"key":"2682_CR364","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1158\/1535-7163.MCT-11-0264","volume":"10","author":"FM Yakes","year":"2011","unstructured":"Yakes, F. M. et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol. Cancer Ther. 10, 2298\u20132308 (2011).","journal-title":"Mol. Cancer Ther."},{"key":"2682_CR365","doi-asserted-by":"publisher","first-page":"4758","DOI":"10.1158\/0008-5472.CAN-10-2527","volume":"71","author":"WK You","year":"2011","unstructured":"You, W. K. et al. VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer. Cancer Res. 71, 4758\u20134768 (2011).","journal-title":"Cancer Res."},{"key":"2682_CR366","doi-asserted-by":"publisher","first-page":"3943","DOI":"10.1158\/1078-0432.CCR-11-0193","volume":"17","author":"KE Torres","year":"2011","unstructured":"Torres, K. E. et al. Activated MET is a molecular prognosticator and potential therapeutic target for malignant peripheral nerve sheath tumors. Clin. Cancer Res. 17, 3943\u20133955 (2011).","journal-title":"Clin. Cancer Res."},{"key":"2682_CR367","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/S1470-2045(23)00097-9","volume":"24","author":"TK Choueiri","year":"2023","unstructured":"Choueiri, T. K. et al. Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 study. Lancet Oncol. 24, 553\u2013562 (2023).","journal-title":"Lancet Oncol."},{"key":"2682_CR368","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/S0140-6736(21)00152-5","volume":"397","author":"SK Pal","year":"2021","unstructured":"Pal, S. K. et al. A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial. Lancet 397, 695\u2013703 (2021).","journal-title":"Lancet"},{"key":"2682_CR369","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/S1470-2045(20)30202-3","volume":"21","author":"AB Apolo","year":"2020","unstructured":"Apolo, A. B. et al. Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial. Lancet Oncol. 21, 1099\u20131109 (2020).","journal-title":"Lancet Oncol."},{"key":"2682_CR370","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1200\/JCO.2012.45.0494","volume":"31","author":"DC Smith","year":"2013","unstructured":"Smith, D. C. et al. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J. Clin. Oncol. 31, 412\u2013419 (2013).","journal-title":"J. Clin. Oncol."},{"key":"2682_CR371","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/s41416-021-01532-5","volume":"126","author":"RK Kelley","year":"2022","unstructured":"Kelley, R. K. et al. Efficacy and safety of cabozantinib for patients with advanced hepatocellular carcinoma based on albumin-bilirubin grade. Br. J. Cancer 126, 569\u2013575 (2022).","journal-title":"Br. J. Cancer"},{"key":"2682_CR372","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s10549-016-4001-y","volume":"160","author":"SM Tolaney","year":"2016","unstructured":"Tolaney, S. M. et al. Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation study. Breast Cancer Res. Treat. 160, 305\u2013312 (2016).","journal-title":"Breast Cancer Res. Treat."},{"key":"2682_CR373","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/bjc.2016.419","volume":"116","author":"A Daud","year":"2017","unstructured":"Daud, A. et al. Phase II randomised discontinuation trial of the MET\/VEGF receptor inhibitor cabozantinib in metastatic melanoma. Br. J. Cancer 116, 432\u2013440 (2017).","journal-title":"Br. J. Cancer"},{"key":"2682_CR374","first-page":"CD012796","volume":"10","author":"F Hofmann","year":"2020","unstructured":"Hofmann, F. et al. Targeted therapy for metastatic renal cell carcinoma. Cochrane Database Syst. Rev. 10, CD012796 (2020).","journal-title":"Cochrane Database Syst. Rev."},{"key":"2682_CR375","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/s41591-020-01193-6","volume":"27","author":"MJ Fisher","year":"2021","unstructured":"Fisher, M. J. et al. Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial. Nat. Med. 27, 165\u2013173 (2021).","journal-title":"Nat. Med."},{"key":"2682_CR376","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ejca.2021.10.033","volume":"161","author":"W van Boxtel","year":"2022","unstructured":"van Boxtel, W. et al. Excessive toxicity of cabozantinib in a phase II study in patients with recurrent and\/or metastatic salivary gland cancer. Eur. J. Cancer 161, 128\u2013137 (2022).","journal-title":"Eur. J. Cancer"},{"key":"2682_CR377","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/j.eururo.2018.11.033","volume":"75","author":"EM Basch","year":"2019","unstructured":"Basch, E. M. et al. Cabozantinib versus mitoxantrone-prednisone in symptomatic metastatic castration-resistant prostate cancer: a randomized phase 3 trial with a primary pain endpoint. Eur. Urol. 75, 929\u2013937 (2019).","journal-title":"Eur. Urol."},{"key":"2682_CR378","doi-asserted-by":"publisher","first-page":"3639","DOI":"10.1200\/JCO.2012.48.4659","volume":"31","author":"R Elisei","year":"2013","unstructured":"Elisei, R. et al. Cabozantinib in progressive medullary thyroid cancer. J. Clin. Oncol. 31, 3639\u20133646 (2013).","journal-title":"J. Clin. Oncol."},{"key":"2682_CR379","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1056\/NEJMoa1717002","volume":"379","author":"GK Abou-Alfa","year":"2018","unstructured":"Abou-Alfa, G. K. et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N. Engl. J. Med. 379, 54\u201363 (2018).","journal-title":"N. Engl. J. Med."},{"key":"2682_CR380","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/S1470-2045(16)30107-3","volume":"17","author":"TK Choueiri","year":"2016","unstructured":"Choueiri, T. K. et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol. 17, 917\u2013927 (2016).","journal-title":"Lancet Oncol."},{"key":"2682_CR381","doi-asserted-by":"publisher","first-page":"4105","DOI":"10.1200\/JCO.2012.47.4189","volume":"31","author":"DR Spigel","year":"2013","unstructured":"Spigel, D. R. et al. Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 31, 4105\u20134114 (2013).","journal-title":"J. Clin. Oncol."},{"key":"2682_CR382","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1056\/NEJMoa1510016","volume":"373","author":"TK Choueiri","year":"2015","unstructured":"Choueiri, T. K. et al. Cabozantinib versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med. 373, 1814\u20131823 (2015).","journal-title":"N. Engl. J. Med."},{"key":"2682_CR383","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1634\/theoncologist.2017-0552","volume":"23","author":"G Rabinowits","year":"2018","unstructured":"Rabinowits, G. et al. Cabozantinib in patients with advanced merkel cell carcinoma. Oncologist 23, 814\u2013821 (2018).","journal-title":"Oncologist"},{"key":"2682_CR384","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/S1470-2045(24)00133-5","volume":"25","author":"C Jimenez","year":"2024","unstructured":"Jimenez, C. et al. Cabozantinib in patients with unresectable and progressive metastatic phaeochromocytoma or paraganglioma (the Natalie Trial): a single-arm, phase 2 trial. Lancet Oncol. 25, 658\u2013667 (2024).","journal-title":"Lancet Oncol."},{"key":"2682_CR385","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1002\/cncr.30571","volume":"123","author":"L Goyal","year":"2017","unstructured":"Goyal, L. et al. A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma. Cancer 123, 1979\u20131988 (2017).","journal-title":"Cancer"},{"key":"2682_CR386","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1158\/1078-0432.CCR-19-2576","volume":"26","author":"NC Dhani","year":"2020","unstructured":"Dhani, N. C. et al. Phase II trial of cabozantinib in recurrent\/metastatic endometrial cancer: a study of the princess Margaret, Chicago, and California Consortia (NCI9322\/PHL86). Clin. Cancer Res. 26, 2477\u20132486 (2020).","journal-title":"Clin. Cancer Res."},{"key":"2682_CR387","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S0140-6736(23)00922-4","volume":"402","author":"SK Pal","year":"2023","unstructured":"Pal, S. K. et al. Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial. Lancet 402, 185\u2013195 (2023).","journal-title":"Lancet"},{"key":"2682_CR388","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1200\/JCO.21.01944","volume":"40","author":"CH Lee","year":"2022","unstructured":"Lee, C. H. et al. Phase II trial of cabozantinib plus nivolumab in patients with non-clear-cell renal cell carcinoma and genomic correlates. J. Clin. Oncol. 40, 2333\u20132341 (2022).","journal-title":"J. Clin. Oncol."},{"key":"2682_CR389","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1158\/1535-7163.MCT-12-1079","volume":"12","author":"S Sharma","year":"2013","unstructured":"Sharma, S. et al. Small-molecule inhibitor BMS-777607 induces breast cancer cell polyploidy with increased resistance to cytotoxic chemotherapy agents. Mol. Cancer Ther. 12, 725\u2013736 (2013).","journal-title":"Mol. Cancer Ther."},{"key":"2682_CR390","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1158\/1535-7163.MCT-10-0359","volume":"9","author":"Y Dai","year":"2010","unstructured":"Dai, Y. & Siemann, D. W. BMS-777607, a small-molecule met kinase inhibitor, suppresses hepatocyte growth factor-stimulated prostate cancer metastatic phenotype in vitro. Mol. Cancer Ther. 9, 1554\u20131561 (2010).","journal-title":"Mol. Cancer Ther."},{"key":"2682_CR391","first-page":"1411","volume":"40","author":"CT Cheng","year":"2018","unstructured":"Cheng, C. T. et al. METRON dual inhibitor, BMS777607, suppresses cholangiocarcinoma cell growth, and METRON upregulation indicates worse prognosis for intrahepatic cholangiocarcinoma patients. Oncol. Rep. 40, 1411\u20131421 (2018).","journal-title":"Oncol. Rep."},{"key":"2682_CR392","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1021\/jm801586s","volume":"52","author":"GM Schroeder","year":"2009","unstructured":"Schroeder, G. M. et al. Discovery of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamily. J. Med. Chem. 52, 1251\u20131254 (2009).","journal-title":"J. Med. Chem."},{"key":"2682_CR393","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1007\/s10637-018-0588-7","volume":"36","author":"A Roohullah","year":"2018","unstructured":"Roohullah, A. et al. A phase I trial to determine safety and pharmacokinetics of ASLAN002, an oral MET superfamily kinase inhibitor, in patients with advanced or metastatic solid cancers. Invest. New Drugs 36, 886\u2013894 (2018).","journal-title":"Invest. New Drugs"},{"key":"2682_CR394","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1007\/s10637-012-9912-9","volume":"31","author":"SB Yan","year":"2013","unstructured":"Yan, S. B. et al. LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models. Invest. New Drugs 31, 833\u2013844 (2013).","journal-title":"Invest. New Drugs"},{"key":"2682_CR395","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1002\/mco2.11","volume":"1","author":"C Zhu","year":"2020","unstructured":"Zhu, C., Shi, H., Wu, M. & Wei, X. A dual MET\/AXL small-molecule inhibitor exerts efficacy against gastric carcinoma through killing cancer cells as well as modulating tumor microenvironment. MedComm 1, 103\u2013118 (2020).","journal-title":"MedComm"},{"key":"2682_CR396","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1007\/s10637-017-0545-x","volume":"36","author":"SB Yan","year":"2018","unstructured":"Yan, S. B. et al. MET-targeting antibody (emibetuzumab) and kinase inhibitor (merestinib) as single agent or in combination in a cancer model bearing MET exon 14 skipping. Invest. New Drugs 36, 536\u2013544 (2018).","journal-title":"Invest. New Drugs"},{"key":"2682_CR397","doi-asserted-by":"publisher","first-page":"e930","DOI":"10.1634\/theoncologist.2018-0411","volume":"24","author":"AR He","year":"2019","unstructured":"He, A. R. et al. First-in-human phase I study of merestinib, an oral multikinase inhibitor, in patients with advanced cancer. Oncologist 24, e930\u2013e942 (2019).","journal-title":"Oncologist"},{"key":"2682_CR398","doi-asserted-by":"publisher","first-page":"6579","DOI":"10.1002\/cam4.4110","volume":"10","author":"T Doi","year":"2021","unstructured":"Doi, T. et al. Merestinib monotherapy or in combination for japanese patients with advanced and\/or metastatic cancer: A phase 1 study. Cancer Med. 10, 6579\u20136589 (2021).","journal-title":"Cancer Med."},{"key":"2682_CR399","doi-asserted-by":"publisher","first-page":"e1628","DOI":"10.1634\/theoncologist.2020-0520","volume":"25","author":"M Saleh","year":"2020","unstructured":"Saleh, M. et al. Phase I study of ramucirumab plus merestinib in previously treated metastatic colorectal cancer: safety, preliminary efficacy, and pharmacokinetic findings. Oncologist 25, e1628\u2013e1639 (2020).","journal-title":"Oncologist"},{"key":"2682_CR400","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1016\/S1470-2045(21)00409-5","volume":"22","author":"JW Valle","year":"2021","unstructured":"Valle, J. W. et al. Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: a randomised, double-blind, multicentre, phase 2 study. Lancet Oncol. 22, 1468\u20131482 (2021).","journal-title":"Lancet Oncol."},{"key":"2682_CR401","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1586\/era.12.16","volume":"12","author":"A Belalcazar","year":"2012","unstructured":"Belalcazar, A. et al. Targeting the Met pathway in lung cancer. Expert Rev. Anticancer Ther. 12, 519\u2013528 (2012).","journal-title":"Expert Rev. Anticancer Ther."},{"key":"2682_CR402","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s11523-022-00875-0","volume":"17","author":"A Patnaik","year":"2022","unstructured":"Patnaik, A. et al. Phase I study of glesatinib (MGCD265) in combination with erlotinib or docetaxel in patients with advanced solid tumors. Target Oncol. 17, 125\u2013138 (2022).","journal-title":"Target Oncol."},{"key":"2682_CR403","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s11523-022-00931-9","volume":"18","author":"C Kollmannsberger","year":"2023","unstructured":"Kollmannsberger, C. et al. Phase I study evaluating glesatinib (MGCD265), an inhibitor of MET and AXL, in patients with non-small cell lung cancer and other advanced solid tumors. Target Oncol. 18, 105\u2013118 (2023).","journal-title":"Target Oncol."},{"key":"2682_CR404","doi-asserted-by":"publisher","first-page":"107512","DOI":"10.1016\/j.lungcan.2024.107512","volume":"190","author":"DS Hong","year":"2024","unstructured":"Hong, D. S. et al. Phase II study investigating the efficacy and safety of glesatinib (MGCD265) in patients with advanced NSCLC containing MET activating alterations. Lung Cancer 190, 107512 (2024).","journal-title":"Lung Cancer"},{"key":"2682_CR405","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1158\/1535-7163.MCT-09-1173","volume":"9","author":"N Munshi","year":"2010","unstructured":"Munshi, N. et al. ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity. Mol. Cancer Ther. 9, 1544\u20131553 (2010).","journal-title":"Mol. Cancer Ther."},{"key":"2682_CR406","doi-asserted-by":"publisher","first-page":"3759","DOI":"10.1111\/cas.14582","volume":"111","author":"M Kudo","year":"2020","unstructured":"Kudo, M. et al. A randomized, double-blind, placebo-controlled, phase 3 study of tivantinib in Japanese patients with MET-high hepatocellular carcinoma. Cancer Sci. 111, 3759\u20133769 (2020).","journal-title":"Cancer Sci."},{"key":"2682_CR407","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/S1470-2045(18)30146-3","volume":"19","author":"L Rimassa","year":"2018","unstructured":"Rimassa, L. et al. Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study. Lancet Oncol. 19, 682\u2013693 (2018).","journal-title":"Lancet Oncol."},{"key":"2682_CR408","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S1470-2045(12)70490-4","volume":"14","author":"A Santoro","year":"2013","unstructured":"Santoro, A. et al. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. Lancet Oncol. 14, 55\u201363 (2013).","journal-title":"Lancet Oncol."},{"key":"2682_CR409","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1158\/1078-0432.CCR-16-1418","volume":"23","author":"LS Rosen","year":"2017","unstructured":"Rosen, L. S. et al. A first-in-human phase I study of a bivalent MET antibody, emibetuzumab (LY2875358), as monotherapy and in combination with erlotinib in advanced cancer. Clin. Cancer Res. 23, 1910\u20131919 (2017).","journal-title":"Clin. Cancer Res."},{"key":"2682_CR410","doi-asserted-by":"publisher","first-page":"S37","DOI":"10.1177\/1758834011423403","volume":"3","author":"N Sharma","year":"2011","unstructured":"Sharma, N. & Adjei, A. A. In the clinic: ongoing clinical trials evaluating c-MET-inhibiting drugs. Ther. Adv. Med. Oncol. 3, S37\u2013S50 (2011).","journal-title":"Ther. Adv. Med. Oncol."},{"key":"2682_CR411","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1200\/JCO.2016.69.2160","volume":"35","author":"DR Spigel","year":"2017","unstructured":"Spigel, D. R. et al. Results from the phase III randomized trial of onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIB or IV non-small-cell lung cancer: METLung. J. Clin. Oncol. 35, 412\u2013420 (2017).","journal-title":"J. Clin. Oncol."},{"key":"2682_CR412","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1586\/14737140.2015.1031219","volume":"15","author":"C Rolfo","year":"2015","unstructured":"Rolfo, C., Van Der Steen, N., Pauwels, P. & Cappuzzo, F. Onartuzumab in lung cancer: the fall of Icarus?. Expert Rev. Anticancer Ther. 15, 487\u2013489 (2015).","journal-title":"Expert Rev. Anticancer Ther."},{"key":"2682_CR413","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.cllc.2016.09.013","volume":"18","author":"H Wakelee","year":"2017","unstructured":"Wakelee, H. et al. Efficacy and safety of onartuzumab in combination with first-line bevacizumab- or pemetrexed-based chemotherapy regimens in advanced non-squamous non-small-cell lung cancer. Clin. Lung Cancer 18, 50\u201359 (2017).","journal-title":"Clin. Lung Cancer"},{"key":"2682_CR414","doi-asserted-by":"publisher","first-page":"3000","DOI":"10.1200\/JCO.24.00720","volume":"42","author":"DR Camidge","year":"2024","unstructured":"Camidge, D. R. et al. Telisotuzumab vedotin monotherapy in patients with previously treated c-met protein-overexpressing advanced nonsquamous EGFR-wildtype non-small cell lung cancer in the phase II LUMINOSITY trial. J. Clin. Oncol. 42, 3000\u20133011 (2024).","journal-title":"J. Clin. Oncol."},{"key":"2682_CR415","doi-asserted-by":"publisher","first-page":"5781","DOI":"10.1158\/1078-0432.CCR-21-0765","volume":"27","author":"DR Camidge","year":"2021","unstructured":"Camidge, D. R. et al. Phase I study of 2- or 3-week dosing of telisotuzumab vedotin, an antibody-drug conjugate targeting c-met, monotherapy in patients with advanced non-small cell lung carcinoma. Clin. Cancer Res. 27, 5781\u20135792 (2021).","journal-title":"Clin. Cancer Res."},{"key":"2682_CR416","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1158\/1078-0432.CCR-16-1568","volume":"23","author":"J Wang","year":"2017","unstructured":"Wang, J. et al. ABBV-399, a c-met antibody-drug conjugate that targets both MET-amplified and c-Met-overexpressing tumors, irrespective of MET pathway dependence. Clin. Cancer Res. 23, 992\u20131000 (2017).","journal-title":"Clin. Cancer Res."},{"key":"2682_CR417","doi-asserted-by":"publisher","first-page":"3298","DOI":"10.1200\/JCO.2018.78.7697","volume":"36","author":"JH Strickler","year":"2018","unstructured":"Strickler, J. H. et al. First-in-human phase I, dose-escalation and -expansion study of telisotuzumab vedotin, an antibody-drug conjugate targeting c-met, in patients with advanced solid tumors. J. Clin. Oncol. 36, 3298\u20133306 (2018).","journal-title":"J. Clin. Oncol."},{"key":"2682_CR418","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1200\/JCO.22.00739","volume":"41","author":"DR Camidge","year":"2023","unstructured":"Camidge, D. R. et al. Phase Ib study of telisotuzumab vedotin in combination with erlotinib in patients with c-met protein-expressing non-small-cell lung cancer. J. Clin. Oncol. 41, 1105\u20131115 (2023).","journal-title":"J. Clin. Oncol."},{"key":"2682_CR419","doi-asserted-by":"publisher","first-page":"7533","DOI":"10.1073\/pnas.1819085116","volume":"116","author":"JB Casaletto","year":"2019","unstructured":"Casaletto, J. B. et al. MM-131, a bispecific anti-Met\/EpCAM mAb, inhibits HGF-dependent and HGF-independent Met signaling through concurrent binding to EpCAM. Proc. Natl. Acad. Sci. USA 116, 7533\u20137542 (2019).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2682_CR420","first-page":"61","volume":"7","author":"M D\u2019Arcangelo","year":"2013","unstructured":"D\u2019Arcangelo, M. & Cappuzzo, F. Focus on the potential role of ficlatuzumab in the treatment of non-small cell lung cancer. Biologics 7, 61\u201368 (2013).","journal-title":"Biologics"},{"key":"2682_CR421","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1001\/jamaoto.2015.2381","volume":"141","author":"D Kumar","year":"2015","unstructured":"Kumar, D. et al. Mitigation of tumor-associated fibroblast-facilitated head and neck cancer progression with anti-hepatocyte growth factor antibody ficlatuzumab. JAMA Otolaryngol. Head. Neck Surg. 141, 1133\u20131139 (2015).","journal-title":"JAMA Otolaryngol. Head. Neck Surg."},{"key":"2682_CR422","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1158\/2643-3230.BCD-21-0055","volume":"2","author":"VE Wang","year":"2021","unstructured":"Wang, V. E. et al. Inhibition of MET signaling with ficlatuzumab in combination with chemotherapy in refractory AML: clinical outcomes and high-dimensional analysis. Blood Cancer Discov. 2, 434\u2013449 (2021).","journal-title":"Blood Cancer Discov."},{"key":"2682_CR423","doi-asserted-by":"crossref","unstructured":"Bauman, J. E. et al. Phase I study of ficlatuzumab and cetuximab in cetuximab-resistant, recurrent\/metastatic head and neck cancer. Cancers (Basel). 12, 1537 (2020).","DOI":"10.3390\/cancers12061537"},{"key":"2682_CR424","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1016\/j.jtho.2016.05.038","volume":"11","author":"TS Mok","year":"2016","unstructured":"Mok, T. S. et al. A Randomized phase 2 study comparing the combination of ficlatuzumab and gefitinib with gefitinib alone in asian patients with advanced stage pulmonary adenocarcinoma. J. Thorac. Oncol. 11, 1736\u20131744 (2016).","journal-title":"J. Thorac. Oncol."},{"key":"2682_CR425","doi-asserted-by":"publisher","first-page":"3851","DOI":"10.1200\/JCO.22.01994","volume":"41","author":"JE Bauman","year":"2023","unstructured":"Bauman, J. E. et al. Randomized phase II trial of ficlatuzumab with or without cetuximab in pan-refractory, recurrent\/metastatic head and neck cancer. J. Clin. Oncol. 41, 3851\u20133862 (2023).","journal-title":"J. Clin. Oncol."},{"key":"2682_CR426","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1093\/oncolo\/oyad002","volume":"28","author":"K Perez","year":"2023","unstructured":"Perez, K. et al. Phase Ib and expansion study of gemcitabine, nab-paclitaxel, and ficlatuzumab in patients with metastatic pancreatic cancer. Oncologist 28, 425\u2013432 (2023).","journal-title":"Oncologist"},{"key":"2682_CR427","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1158\/1535-7163.MCT-09-0824","volume":"9","author":"TL Burgess","year":"2010","unstructured":"Burgess, T. L. et al. Biochemical characterization of AMG 102: a neutralizing, fully human monoclonal antibody to human and nonhuman primate hepatocyte growth factor. Mol. Cancer Ther. 9, 400\u2013409 (2010).","journal-title":"Mol. Cancer Ther."},{"key":"2682_CR428","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1158\/1078-0432.CCR-14-1661","volume":"21","author":"S Doshi","year":"2015","unstructured":"Doshi, S. et al. Rilotumumab exposure-response relationship in patients with advanced or metastatic gastric cancer. Clin. Cancer Res. 21, 2453\u20132461 (2015).","journal-title":"Clin. Cancer Res."},{"key":"2682_CR429","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1158\/1078-0432.CCR-09-1365","volume":"16","author":"MS Gordon","year":"2010","unstructured":"Gordon, M. S. et al. Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors. Clin. Cancer Res. 16, 699\u2013710 (2010).","journal-title":"Clin. Cancer Res."},{"key":"2682_CR430","doi-asserted-by":"publisher","first-page":"2936","DOI":"10.1002\/cncr.30717","volume":"123","author":"AA Tarhini","year":"2017","unstructured":"Tarhini, A. A. et al. Phase 1\/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non-small cell lung cancer. Cancer 123, 2936\u20132944 (2017).","journal-title":"Cancer"},{"key":"2682_CR431","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/S1470-2045(14)70023-3","volume":"15","author":"T Iveson","year":"2014","unstructured":"Iveson, T. et al. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study. Lancet Oncol. 15, 1007\u20131018 (2014).","journal-title":"Lancet Oncol."},{"key":"2682_CR432","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1016\/S1470-2045(17)30566-1","volume":"18","author":"DVT Catenacci","year":"2017","unstructured":"Catenacci, D. V. T. et al. Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 18, 1467\u20131482 (2017).","journal-title":"Lancet Oncol."},{"key":"2682_CR433","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.ygyno.2013.12.018","volume":"132","author":"LP Martin","year":"2014","unstructured":"Martin, L. P. et al. A phase II evaluation of AMG 102 (rilotumumab) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol. Oncol. 132, 526\u2013530 (2014).","journal-title":"Gynecol. Oncol."},{"key":"2682_CR434","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1158\/1078-0432.CCR-12-2605","volume":"19","author":"CJ Ryan","year":"2013","unstructured":"Ryan, C. J. et al. Targeted MET inhibition in castration-resistant prostate cancer: a randomized phase II study and biomarker analysis with rilotumumab plus mitoxantrone and prednisone. Clin. Cancer Res. 19, 215\u2013224 (2013).","journal-title":"Clin. Cancer Res."},{"key":"2682_CR435","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.4014\/jmb.1306.06007","volume":"23","author":"SW Song","year":"2013","unstructured":"Song, S. W. et al. Inhibition of tumor growth in a mouse xenograft model by the humanized anti-HGF monoclonal antibody YYB-101 produced in a large-scale CHO cell culture. J. Microbiol. Biotechnol. 23, 1327\u20131338 (2013).","journal-title":"J. Microbiol. Biotechnol."},{"key":"2682_CR436","doi-asserted-by":"crossref","unstructured":"Kim, S. et al. Efficient selection of antibodies reactive to homologous epitopes on human and mouse hepatocyte growth factors by next-generation sequencing-based analysis of the B cell repertoire. Int. J. Mol. Sci. 20, 417 (2019).","DOI":"10.3390\/ijms20020417"},{"key":"2682_CR437","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1093\/neuonc\/noy105","volume":"21","author":"JK Sa","year":"2019","unstructured":"Sa, J. K. et al. Identification of genomic and molecular traits that present therapeutic vulnerability to HGF-targeted therapy in glioblastoma. Neuro Oncol. 21, 222\u2013233 (2019).","journal-title":"Neuro Oncol."},{"key":"2682_CR438","doi-asserted-by":"publisher","DOI":"10.1038\/emm.2017.21","volume":"49","author":"H Kim","year":"2017","unstructured":"Kim, H. et al. Preclinical development of a humanized neutralizing antibody targeting HGF. Exp. Mol. Med. 49, e309 (2017).","journal-title":"Exp. Mol. Med."},{"key":"2682_CR439","doi-asserted-by":"publisher","first-page":"571","DOI":"10.3389\/fonc.2019.00571","volume":"9","author":"HJ Kim","year":"2019","unstructured":"Kim, H. J. et al. Humanized anti-hepatocyte growth factor monoclonal antibody (YYB-101) inhibits ovarian cancer progression. Front. Oncol. 9, 571 (2019).","journal-title":"Front. Oncol."},{"key":"2682_CR440","doi-asserted-by":"publisher","first-page":"671","DOI":"10.21873\/anticanres.14818","volume":"41","author":"HJ Kim","year":"2021","unstructured":"Kim, H. J. & Heo, K. YYB-101, a humanized antihepatocyte growth factor monoclonal antibody, inhibits ovarian cancer cell motility and proliferation. Anticancer Res. 41, 671\u2013678 (2021).","journal-title":"Anticancer Res."},{"key":"2682_CR441","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1158\/1535-7163.MCT-10-0481","volume":"9","author":"W Okamoto","year":"2010","unstructured":"Okamoto, W. et al. TAK-701, a humanized monoclonal antibody to hepatocyte growth factor, reverses gefitinib resistance induced by tumor-derived HGF in non-small cell lung cancer with an EGFR mutation. Mol. Cancer Ther. 9, 2785\u20132792 (2010).","journal-title":"Mol. Cancer Ther."},{"key":"2682_CR442","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1002\/pbc.24756","volume":"61","author":"PJ Houghton","year":"2014","unstructured":"Houghton, P. J. et al. Initial testing (Stage 1) of TAK-701, a humanized hepatocyte growth factor binding antibody, by the pediatric preclinical testing program. Pediatr. Blood Cancer 61, 380\u2013382 (2014).","journal-title":"Pediatr. Blood Cancer"},{"key":"2682_CR443","doi-asserted-by":"publisher","first-page":"6861","DOI":"10.1093\/nar\/gku382","volume":"42","author":"T Hayashi","year":"2014","unstructured":"Hayashi, T. et al. Binding of an RNA aptamer and a partial peptide of a prion protein: crucial importance of water entropy in molecular recognition. Nucleic Acids Res. 42, 6861\u20136875 (2014).","journal-title":"Nucleic Acids Res."},{"key":"2682_CR444","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1126\/science.287.5454.820","volume":"287","author":"T Hermann","year":"2000","unstructured":"Hermann, T. & Patel, D. J. Adaptive recognition by nucleic acid aptamers. Science 287, 820\u2013825 (2000).","journal-title":"Science"},{"key":"2682_CR445","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-1090-3","volume":"18","author":"C Zhu","year":"2019","unstructured":"Zhu, C., Wei, Y. & Wei, X. AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications. Mol. Cancer 18, 153 (2019).","journal-title":"Mol. Cancer"},{"key":"2682_CR446","doi-asserted-by":"crossref","unstructured":"Lee, M. et al. Recent advances and prospects of nucleic acid therapeutics for anti-cancer therapy. Molecules. 29, 447 (2024).","DOI":"10.3390\/molecules29194737"},{"key":"2682_CR447","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1038\/mt.2012.163","volume":"20","author":"L Cerchia","year":"2012","unstructured":"Cerchia, L. et al. Targeting Axl with an high-affinity inhibitory aptamer. Mol. Ther. 20, 2291\u20132303 (2012).","journal-title":"Mol. Ther."},{"key":"2682_CR448","first-page":"487","volume":"11","author":"CL Esposito","year":"2011","unstructured":"Esposito, C. L., Catuogno, S., de Franciscis, V. & Cerchia, L. New insight into clinical development of nucleic acid aptamers. Discov. Med. 11, 487\u2013496 (2011).","journal-title":"Discov. Med."},{"key":"2682_CR449","doi-asserted-by":"publisher","first-page":"13131","DOI":"10.1039\/C4CC06016D","volume":"50","author":"R Ueki","year":"2014","unstructured":"Ueki, R. & Sando, S. A DNA aptamer to c-Met inhibits cancer cell migration. Chem. Commun. 50, 13131\u201313134 (2014).","journal-title":"Chem. Commun."},{"key":"2682_CR450","doi-asserted-by":"publisher","first-page":"5978","DOI":"10.1111\/jcmm.13870","volume":"22","author":"Y Zhang","year":"2018","unstructured":"Zhang, Y. et al. Targeting c-met receptor tyrosine kinase by the DNA aptamer SL1 as a potential novel therapeutic option for myeloma. J. Cell Mol. Med. 22, 5978\u20135990 (2018).","journal-title":"J. Cell Mol. Med."},{"key":"2682_CR451","doi-asserted-by":"publisher","first-page":"5090","DOI":"10.1073\/pnas.0508156103","volume":"103","author":"A Petrelli","year":"2006","unstructured":"Petrelli, A. et al. Ab-induced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activity. Proc. Natl. Acad. Sci. USA 103, 5090\u20135095 (2006).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2682_CR452","first-page":"5954","volume":"11","author":"M Prat","year":"1991","unstructured":"Prat, M. et al. C-terminal truncated forms of Met, the hepatocyte growth factor receptor. Mol. Cell Biol. 11, 5954\u20135962 (1991).","journal-title":"Mol. Cell Biol."},{"key":"2682_CR453","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1158\/1535-7163.MCT-08-1032","volume":"8","author":"A Coxon","year":"2009","unstructured":"Coxon, A. et al. Soluble c-Met receptors inhibit phosphorylation of c-Met and growth of hepatocyte growth factor: c-Met-dependent tumors in animal models. Mol. Cancer Ther. 8, 1119\u20131125 (2009).","journal-title":"Mol. Cancer Ther."},{"key":"2682_CR454","doi-asserted-by":"publisher","first-page":"21267","DOI":"10.1074\/jbc.M800727200","volume":"283","author":"C Basilico","year":"2008","unstructured":"Basilico, C. et al. A high affinity hepatocyte growth factor-binding site in the immunoglobulin-like region of Met. J. Biol. Chem. 283, 21267\u201321277 (2008).","journal-title":"J. Biol. Chem."},{"key":"2682_CR455","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1002\/ijc.27861","volume":"132","author":"JJ Yang","year":"2013","unstructured":"Yang, J. J. et al. Soluble c-Met protein as a susceptible biomarker for gastric cancer risk: a nested case-control study within the Korean Multicenter Cancer Cohort. Int J. Cancer 132, 2148\u20132156 (2013).","journal-title":"Int J. Cancer"},{"key":"2682_CR456","doi-asserted-by":"publisher","first-page":"2728","DOI":"10.3390\/molecules20022728","volume":"20","author":"MK Shanmugam","year":"2015","unstructured":"Shanmugam, M. K. et al. The multifaceted role of curcumin in cancer prevention and treatment. Molecules 20, 2728\u20132769 (2015).","journal-title":"Molecules"},{"key":"2682_CR457","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1080\/01635581.2011.523502","volume":"63","author":"MK Shanmugam","year":"2011","unstructured":"Shanmugam, M. K., Kannaiyan, R. & Sethi, G. Targeting cell signaling and apoptotic pathways by dietary agents: role in the prevention and treatment of cancer. Nutr. Cancer 63, 161\u2013173 (2011).","journal-title":"Nutr. Cancer"},{"key":"2682_CR458","first-page":"363","volume":"23","author":"BB Aggarwal","year":"2003","unstructured":"Aggarwal, B. B., Kumar, A. & Bharti, A. C. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res. 23, 363\u2013398 (2003).","journal-title":"Anticancer Res."},{"key":"2682_CR459","doi-asserted-by":"publisher","first-page":"6847","DOI":"10.1158\/1078-0432.CCR-04-0744","volume":"10","author":"RA Sharma","year":"2004","unstructured":"Sharma, R. A. et al. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin. Cancer Res. 10, 6847\u20136854 (2004).","journal-title":"Clin. Cancer Res."},{"key":"2682_CR460","first-page":"4177","volume":"19","author":"Y Ohnishi","year":"2020","unstructured":"Ohnishi, Y. et al. Curcumin inhibits epithelial-mesenchymal transition in oral cancer cells via c-Met blockade. Oncol. Lett. 19, 4177\u20134182 (2020).","journal-title":"Oncol. Lett."},{"key":"2682_CR461","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-8-135","volume":"8","author":"S Simonetti","year":"2010","unstructured":"Simonetti, S. et al. Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small-cell lung cancer. J. Transl. Med. 8, 135 (2010).","journal-title":"J. Transl. Med."},{"key":"2682_CR462","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1158\/0008-5472.CAN-06-3339","volume":"67","author":"T Okabe","year":"2007","unstructured":"Okabe, T. et al. Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplification. Cancer Res. 67, 2046\u20132053 (2007).","journal-title":"Cancer Res."},{"key":"2682_CR463","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1038\/sj.onc.1203404","volume":"19","author":"DW Seol","year":"2000","unstructured":"Seol, D. W., Chen, Q. & Zarnegar, R. Transcriptional activation of the hepatocyte growth factor receptor (c-met) gene by its ligand (hepatocyte growth factor) is mediated through AP-1. Oncogene 19, 1132\u20131137 (2000).","journal-title":"Oncogene"},{"key":"2682_CR464","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1002\/ptr.5056","volume":"28","author":"Y Yamauchi","year":"2014","unstructured":"Yamauchi, Y., Izumi, Y., Yamamoto, J. & Nomori, H. Coadministration of erlotinib and curcumin augmentatively reduces cell viability in lung cancer cells. Phytother. Res. 28, 728\u2013735 (2014).","journal-title":"Phytother. Res."},{"key":"2682_CR465","doi-asserted-by":"publisher","first-page":"6741","DOI":"10.1002\/jcb.27972","volume":"120","author":"HJ Shin","year":"2019","unstructured":"Shin, H. J., Lee, S. & Jung, H. J. A curcumin derivative hydrazinobenzoylcurcumin suppresses stem-like features of glioblastoma cells by targeting Ca(2\u2009+\u2009) \/calmodulin-dependent protein kinase II. J. Cell Biochem. 120, 6741\u20136752 (2019).","journal-title":"J. Cell Biochem."},{"key":"2682_CR466","doi-asserted-by":"publisher","first-page":"503","DOI":"10.2174\/1570161115666170713094319","volume":"15","author":"MK Shanmugam","year":"2017","unstructured":"Shanmugam, M. K. et al. Potential role of natural compounds as anti-angiogenic agents in cancer. Curr. Vasc. Pharm. 15, 503\u2013519 (2017).","journal-title":"Curr. Vasc. Pharm."},{"key":"2682_CR467","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.canlet.2010.10.025","volume":"303","author":"R Kannaiyan","year":"2011","unstructured":"Kannaiyan, R., Shanmugam, M. K. & Sethi, G. Molecular targets of celastrol derived from thunder of god vine: potential role in the treatment of inflammatory disorders and cancer. Cancer Lett. 303, 9\u201320 (2011).","journal-title":"Cancer Lett."},{"key":"2682_CR468","doi-asserted-by":"publisher","first-page":"4203","DOI":"10.1007\/s11033-013-2501-y","volume":"40","author":"HL Jiang","year":"2013","unstructured":"Jiang, H. L. et al. Celastrol exerts synergistic effects with PHA-665752 and inhibits tumor growth of c-Met-deficient hepatocellular carcinoma in vivo. Mol. Biol. Rep. 40, 4203\u20134209 (2013).","journal-title":"Mol. Biol. Rep."},{"key":"2682_CR469","doi-asserted-by":"publisher","first-page":"155379","DOI":"10.1016\/j.phymed.2024.155379","volume":"128","author":"CD Mohan","year":"2024","unstructured":"Mohan, C. D. et al. c-MET pathway in human malignancies and its targeting by natural compounds for cancer therapy. Phytomedicine 128, 155379 (2024).","journal-title":"Phytomedicine"},{"key":"2682_CR470","doi-asserted-by":"publisher","first-page":"3262S","DOI":"10.1093\/jn\/133.10.3262S","volume":"133","author":"JD Lambert","year":"2003","unstructured":"Lambert, J. D. & Yang, C. S. Mechanisms of cancer prevention by tea constituents. J. Nutr. 133, 3262S\u20133267S (2003).","journal-title":"J. Nutr."},{"key":"2682_CR471","doi-asserted-by":"publisher","first-page":"3431S","DOI":"10.1093\/jn\/134.12.3431S","volume":"134","author":"V Crespy","year":"2004","unstructured":"Crespy, V. & Williamson, G. A review of the health effects of green tea catechins in in vivo animal models. J. Nutr. 134, 3431S\u20133440S (2004).","journal-title":"J. Nutr."},{"key":"2682_CR472","doi-asserted-by":"publisher","first-page":"111","DOI":"10.3858\/emm.2011.43.2.013","volume":"43","author":"IH Kwak","year":"2011","unstructured":"Kwak, I. H. et al. Epigallocatechin-3-gallate inhibits paracrine and autocrine hepatocyte growth factor\/scatter factor-induced tumor cell migration and invasion. Exp. Mol. Med. 43, 111\u2013120 (2011).","journal-title":"Exp. Mol. Med."},{"key":"2682_CR473","first-page":"739","volume":"49","author":"D Duhon","year":"2010","unstructured":"Duhon, D. et al. The polyphenol epigallocatechin-3-gallate affects lipid rafts to block activation of the c-Met receptor in prostate cancer cells. Mol. Carcinog. 49, 739\u2013749 (2010).","journal-title":"Mol. Carcinog."},{"key":"2682_CR474","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.abb.2010.03.017","volume":"501","author":"CA Larsen","year":"2010","unstructured":"Larsen, C. A. & Dashwood, R. H. (\u2013)-Epigallocatechin-3-gallate inhibits Met signaling, proliferation, and invasiveness in human colon cancer cells. Arch. Biochem. Biophys. 501, 52\u201357 (2010).","journal-title":"Arch. Biochem. Biophys."},{"key":"2682_CR475","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.bbrc.2009.09.019","volume":"389","author":"CA Larsen","year":"2009","unstructured":"Larsen, C. A. & Dashwood, R. H. Suppression of Met activation in human colon cancer cells treated with (-)-epigallocatechin-3-gallate: minor role of hydrogen peroxide. Biochem. Biophys. Res. Commun. 389, 527\u2013530 (2009).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2682_CR476","doi-asserted-by":"publisher","first-page":"4885","DOI":"10.1158\/1078-0432.CCR-09-0109","volume":"15","author":"SA Milligan","year":"2009","unstructured":"Milligan, S. A. et al. The green tea polyphenol EGCG potentiates the antiproliferative activity of c-Met and epidermal growth factor receptor inhibitors in non-small cell lung cancer cells. Clin. Cancer Res. 15, 4885\u20134894 (2009).","journal-title":"Clin. Cancer Res."},{"key":"2682_CR477","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.canlet.2008.05.048","volume":"271","author":"YC Lim","year":"2008","unstructured":"Lim, Y. C. et al. (-)-Epigallocatechin-3-gallate (EGCG) inhibits HGF-induced invasion and metastasis in hypopharyngeal carcinoma cells. Cancer Lett. 271, 140\u2013152 (2008).","journal-title":"Cancer Lett."},{"key":"2682_CR478","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1038\/sj.onc.1209227","volume":"25","author":"RL Bigelow","year":"2006","unstructured":"Bigelow, R. L. & Cardelli, J. A. The green tea catechins, (-)-Epigallocatechin-3-gallate (EGCG) and (-)-Epicatechin-3-gallate (ECG), inhibit HGF\/Met signaling in immortalized and tumorigenic breast epithelial cells. Oncogene 25, 1922\u20131930 (2006).","journal-title":"Oncogene"},{"key":"2682_CR479","doi-asserted-by":"publisher","first-page":"4373","DOI":"10.1007\/s13277-015-4187-3","volume":"37","author":"K Zhu","year":"2016","unstructured":"Zhu, K. & Wang, W. Green tea polyphenol EGCG suppresses osteosarcoma cell growth through upregulating miR-1. Tumour Biol. 37, 4373\u20134382 (2016).","journal-title":"Tumour Biol."},{"key":"2682_CR480","doi-asserted-by":"publisher","first-page":"8554","DOI":"10.1073\/pnas.141230798","volume":"98","author":"KM Sakamoto","year":"2001","unstructured":"Sakamoto, K. M. et al. Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation. Proc. Natl. Acad. Sci. USA 98, 8554\u20138559 (2001).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2682_CR481","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1038\/s42003-020-0868-6","volume":"3","author":"A Mares","year":"2020","unstructured":"Mares, A. et al. Extended pharmacodynamic responses observed upon PROTAC-mediated degradation of RIPK2. Commun. Biol. 3, 140 (2020).","journal-title":"Commun. Biol."},{"key":"2682_CR482","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.chembiol.2017.09.009","volume":"25","author":"GM Burslem","year":"2018","unstructured":"Burslem, G. M. et al. The advantages of targeted protein degradation over inhibition: an RTK case study. Cell Chem. Biol. 25, 67\u201377 e63 (2018).","journal-title":"Cell Chem. Biol."},{"key":"2682_CR483","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1021\/acscentsci.0c00411","volume":"6","author":"MJ Bond","year":"2020","unstructured":"Bond, M. J. et al. Targeted degradation of oncogenic KRAS(G12C) by VHL-recruiting PROTACs. ACS Cent. Sci. 6, 1367\u20131375 (2020).","journal-title":"ACS Cent. Sci."},{"key":"2682_CR484","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1021\/acs.jmedchem.8b01631","volume":"62","author":"X Han","year":"2019","unstructured":"Han, X. et al. Discovery of ARD-69 as a highly potent proteolysis targeting chimera (PROTAC) degrader of androgen receptor (AR) for the treatment of prostate cancer. J. Med. Chem. 62, 941\u2013964 (2019).","journal-title":"J. Med. Chem."},{"key":"2682_CR485","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/s41422-019-0144-9","volume":"29","author":"J Guo","year":"2019","unstructured":"Guo, J., Liu, J. & Wei, W. Degrading proteins in animals: \u201cPROTAC\u201ction goes in vivo. Cell Res. 29, 179\u2013180 (2019).","journal-title":"Cell Res."},{"key":"2682_CR486","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/nchembio.1858","volume":"11","author":"DP Bondeson","year":"2015","unstructured":"Bondeson, D. P. et al. Catalytic in vivo protein knockdown by small-molecule PROTACs. Nat. Chem. Biol. 11, 611\u2013617 (2015).","journal-title":"Nat. Chem. Biol."},{"key":"2682_CR487","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","volume":"21","author":"M Bekes","year":"2022","unstructured":"Bekes, M., Langley, D. R. & Crews, C. M. PROTAC targeted protein degraders: the past is prologue. Nat. Rev. Drug Discov. 21, 181\u2013200 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2682_CR488","doi-asserted-by":"publisher","first-page":"11280","DOI":"10.1021\/acs.jmedchem.9b01530","volume":"62","author":"H Zhou","year":"2019","unstructured":"Zhou, H. et al. Structure-based discovery of SD-36 as a potent, selective, and efficacious PROTAC degrader of STAT3 protein. J. Med. Chem. 62, 11280\u201311300 (2019).","journal-title":"J. Med. Chem."},{"key":"2682_CR489","doi-asserted-by":"publisher","first-page":"12831","DOI":"10.1021\/acs.jmedchem.1c00882","volume":"64","author":"X Han","year":"2021","unstructured":"Han, X. et al. Strategies toward discovery of potent and orally bioavailable proteolysis targeting chimera degraders of androgen receptor for the treatment of prostate cancer. J. Med. Chem. 64, 12831\u201312854 (2021).","journal-title":"J. Med. Chem."},{"key":"2682_CR490","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1021\/acs.jmedchem.8b01572","volume":"62","author":"J Hu","year":"2019","unstructured":"Hu, J. et al. Discovery of ERD-308 as a highly potent proteolysis targeting chimera (PROTAC) degrader of estrogen receptor (ER). J. Med. Chem. 62, 1420\u20131442 (2019).","journal-title":"J. Med. Chem."},{"key":"2682_CR491","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.ejmech.2018.03.071","volume":"151","author":"C Zhang","year":"2018","unstructured":"Zhang, C. et al. Proteolysis targeting chimeras (PROTACs) of anaplastic lymphoma kinase (ALK). Eur. J. Med. Chem. 151, 304\u2013314 (2018).","journal-title":"Eur. J. Med. Chem."},{"key":"2682_CR492","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/s43018-021-00174-z","volume":"2","author":"X Wu","year":"2021","unstructured":"Wu, X. et al. Distinct CDK6 complexes determine tumor cell response to CDK4\/6 inhibitors and degraders. Nat. Cancer 2, 429\u2013443 (2021).","journal-title":"Nat. Cancer"},{"key":"2682_CR493","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1021\/acs.jmedchem.9b01566","volume":"63","author":"M Cheng","year":"2020","unstructured":"Cheng, M. et al. Discovery of potent and selective epidermal growth factor receptor (EGFR) Bifunctional small-molecule degraders. J. Med. Chem. 63, 1216\u20131232 (2020).","journal-title":"J. Med. Chem."},{"key":"2682_CR494","doi-asserted-by":"publisher","first-page":"9120","DOI":"10.1021\/acs.jmedchem.1c00270","volume":"64","author":"S Xie","year":"2021","unstructured":"Xie, S. et al. Development of alectinib-based PROTACs as novel potent degraders of anaplastic lymphoma kinase (ALK). J. Med. Chem. 64, 9120\u20139140 (2021).","journal-title":"J. Med. Chem."},{"key":"2682_CR495","doi-asserted-by":"publisher","first-page":"11066","DOI":"10.1021\/acs.jmedchem.2c00384","volume":"65","author":"J Yang","year":"2022","unstructured":"Yang, J. et al. Discovery of a highly potent and selective dual PROTAC degrader of CDK12 and CDK13. J. Med. Chem. 65, 11066\u201311083 (2022).","journal-title":"J. Med. Chem."},{"key":"2682_CR496","doi-asserted-by":"publisher","first-page":"11034","DOI":"10.1021\/acs.jmedchem.2c00257","volume":"65","author":"J Li","year":"2022","unstructured":"Li, J. et al. Discovery of small-molecule degraders of the CDK9-cyclin T1 complex for targeting transcriptional addiction in prostate cancer. J. Med. Chem. 65, 11034\u201311057 (2022).","journal-title":"J. Med. Chem."},{"key":"2682_CR497","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/s41589-021-00742-5","volume":"17","author":"L Wang","year":"2021","unstructured":"Wang, L. et al. Discovery of a first-in-class CDK2 selective degrader for AML differentiation therapy. Nat. Chem. Biol. 17, 567\u2013575 (2021).","journal-title":"Nat. Chem. Biol."},{"key":"2682_CR498","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1038\/s41422-018-0055-1","volume":"28","author":"Y Sun","year":"2018","unstructured":"Sun, Y. et al. PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies. Cell Res. 28, 779\u2013781 (2018).","journal-title":"Cell Res."},{"key":"2682_CR499","doi-asserted-by":"publisher","first-page":"112199","DOI":"10.1016\/j.ejmech.2020.112199","volume":"192","author":"X Zhang","year":"2020","unstructured":"Zhang, X. et al. Design and synthesis of selective degraders of EGFR(L858R\/T790M) mutant. Eur. J. Med. Chem. 192, 112199 (2020).","journal-title":"Eur. J. Med. Chem."},{"key":"2682_CR500","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1038\/s41556-022-00850-x","volume":"24","author":"J Wang","year":"2022","unstructured":"Wang, J. et al. EZH2 noncanonically binds cMyc and p300 through a cryptic transactivation domain to mediate gene activation and promote oncogenesis. Nat. Cell Biol. 24, 384\u2013399 (2022).","journal-title":"Nat. Cell Biol."},{"key":"2682_CR501","doi-asserted-by":"publisher","first-page":"10611","DOI":"10.1021\/acs.jmedchem.2c00807","volume":"65","author":"F Meng","year":"2022","unstructured":"Meng, F. et al. Discovery of a first-in-class degrader for nuclear receptor binding SET domain protein 2 (NSD2) and Ikaros\/Aiolos. J. Med. Chem. 65, 10611\u201310625 (2022).","journal-title":"J. Med. Chem."},{"key":"2682_CR502","doi-asserted-by":"publisher","first-page":"2829","DOI":"10.1021\/acs.jmedchem.0c02234","volume":"64","author":"Z Liu","year":"2021","unstructured":"Liu, Z. et al. Design and synthesis of EZH2-based PROTACs to degrade the PRC2 complex for targeting the noncatalytic activity of EZH2. J. Med. Chem. 64, 2829\u20132848 (2021).","journal-title":"J. Med. Chem."},{"key":"2682_CR503","doi-asserted-by":"publisher","first-page":"6685","DOI":"10.1021\/acs.jmedchem.8b00506","volume":"61","author":"C Qin","year":"2018","unstructured":"Qin, C. et al. Discovery of QCA570 as an exceptionally potent and efficacious proteolysis targeting chimera (PROTAC) degrader of the bromodomain and extra-terminal (BET) proteins capable of inducing complete and durable tumor regression. J. Med. Chem. 61, 6685\u20136704 (2018).","journal-title":"J. Med. Chem."},{"key":"2682_CR504","doi-asserted-by":"publisher","first-page":"15642","DOI":"10.1021\/acs.jmedchem.2c00771","volume":"65","author":"LR Bollu","year":"2022","unstructured":"Bollu, L. R. et al. Identification and characterization of a novel indoleamine 2,3-dioxygenase 1 protein degrader for glioblastoma. J. Med. Chem. 65, 15642\u201315662 (2022).","journal-title":"J. Med. Chem."},{"key":"2682_CR505","doi-asserted-by":"publisher","first-page":"6593","DOI":"10.1021\/acs.jmedchem.1c01948","volume":"65","author":"J Liu","year":"2022","unstructured":"Liu, J. et al. Novel CRBN-recruiting proteolysis-targeting chimeras as degraders of stimulator of interferon genes with in vivo anti-inflammatory efficacy. J. Med. Chem. 65, 6593\u20136611 (2022).","journal-title":"J. Med. Chem."},{"key":"2682_CR506","doi-asserted-by":"publisher","first-page":"104833","DOI":"10.1016\/j.bioorg.2021.104833","volume":"111","author":"Y Wang","year":"2021","unstructured":"Wang, Y. et al. In vitro and in vivo degradation of programmed cell death ligand 1 (PD-L1) by a proteolysis targeting chimera (PROTAC). Bioorg. Chem. 111, 104833 (2021).","journal-title":"Bioorg. Chem."},{"key":"2682_CR507","doi-asserted-by":"publisher","first-page":"4061","DOI":"10.1038\/s41388-021-01835-0","volume":"40","author":"M Fernandes","year":"2021","unstructured":"Fernandes, M. et al. When the MET receptor kicks in to resist targeted therapies. Oncogene 40, 4061\u20134078 (2021).","journal-title":"Oncogene"},{"key":"2682_CR508","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1111\/cas.15733","volume":"114","author":"JJ Chen","year":"2023","unstructured":"Chen, J. J. et al. Crizotinib-based proteolysis targeting chimera suppresses gastric cancer by promoting MET degradation. Cancer Sci. 114, 1958\u20131971 (2023).","journal-title":"Cancer Sci."},{"key":"2682_CR509","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1016\/j.apsb.2023.01.014","volume":"13","author":"P Li","year":"2023","unstructured":"Li, P. et al. Discovery of novel exceptionally potent and orally active c-MET PROTACs for the treatment of tumors with MET alterations. Acta Pharm. Sin. B 13, 2715\u20132735 (2023).","journal-title":"Acta Pharm. Sin. B"},{"key":"2682_CR510","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.chembiol.2017.09.010","volume":"25","author":"DP Bondeson","year":"2018","unstructured":"Bondeson, D. P. et al. Lessons in PROTAC design from selective degradation with a promiscuous warhead. Cell Chem. Biol. 25, 78\u201387 e75 (2018).","journal-title":"Cell Chem. Biol."},{"key":"2682_CR511","doi-asserted-by":"publisher","first-page":"10419","DOI":"10.1039\/D5RA01441G","volume":"15","author":"JR Mallareddy","year":"2025","unstructured":"Mallareddy, J. R. et al. Fluorescence based live cell imaging identifies exon 14 skipped hepatocyte growth factor receptor (MET) degraders. RSC Adv. 15, 10419\u201310425 (2025).","journal-title":"RSC Adv."},{"key":"2682_CR512","doi-asserted-by":"publisher","first-page":"17053","DOI":"10.1021\/acs.jmedchem.3c02417","volume":"67","author":"S Ying","year":"2024","unstructured":"Ying, S. et al. Selective and orally bioavailable c-Met PROTACs for the treatment of c-met-addicted cancer. J. Med. Chem. 67, 17053\u201317069 (2024).","journal-title":"J. Med. Chem."},{"key":"2682_CR513","doi-asserted-by":"crossref","unstructured":"Sachkova, A. A. et al. Design, synthesis and in vitro investigation of cabozantinib-based PROTACs to target c-met kinase. Pharmaceutics. 14, 2829 (2022).","DOI":"10.3390\/pharmaceutics14122829"},{"key":"2682_CR514","doi-asserted-by":"publisher","first-page":"11615","DOI":"10.1021\/acs.jmedchem.0c00793","volume":"63","author":"L Goracci","year":"2020","unstructured":"Goracci, L. et al. Understanding the metabolism of proteolysis targeting chimeras (PROTACs): the next step toward pharmaceutical applications. J. Med. Chem. 63, 11615\u201311638 (2020).","journal-title":"J. Med. Chem."},{"key":"2682_CR515","first-page":"100630","volume":"5","author":"Y Han","year":"2024","unstructured":"Han, Y. et al. Targeting MET in NSCLC: an ever-expanding territory. JTO Clin. Res. Rep. 5, 100630 (2024).","journal-title":"JTO Clin. Res. Rep."},{"key":"2682_CR516","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.1200\/JCO.2014.60.7317","volume":"33","author":"G Scagliotti","year":"2015","unstructured":"Scagliotti, G. et al. Phase III multinational, randomized, double-blind, placebo-controlled study of tivantinib (ARQ 197) plus erlotinib versus erlotinib alone in previously treated patients with locally advanced or metastatic nonsquamous non-small-cell lung cancer. J. Clin. Oncol. 33, 2667\u20132674 (2015).","journal-title":"J. Clin. Oncol."},{"key":"2682_CR517","doi-asserted-by":"publisher","first-page":"e441","DOI":"10.1016\/j.cllc.2018.03.010","volume":"19","author":"H Reis","year":"2018","unstructured":"Reis, H. et al. MET expression in advanced non-small-cell lung cancer: effect on clinical outcomes of chemotherapy, targeted therapy, and immunotherapy. Clin. Lung Cancer 19, e441\u2013e463 (2018).","journal-title":"Clin. Lung Cancer"},{"key":"2682_CR518","doi-asserted-by":"publisher","first-page":"6661","DOI":"10.1158\/1078-0432.CCR-17-1192","volume":"23","author":"LD Engstrom","year":"2017","unstructured":"Engstrom, L. D. et al. Glesatinib exhibits antitumor activity in lung cancer models and patients harboring MET Exon 14 mutations and overcomes mutation-mediated resistance to type I MET inhibitors in nonclinical models. Clin. Cancer Res. 23, 6661\u20136672 (2017).","journal-title":"Clin. Cancer Res."},{"key":"2682_CR519","first-page":"83","volume":"3","author":"G Finocchiaro","year":"2015","unstructured":"Finocchiaro, G. et al. Prognostic and predictive value of MET deregulation in non-small cell lung cancer. Ann. Transl. Med. 3, 83 (2015).","journal-title":"Ann. Transl. Med."},{"key":"2682_CR520","doi-asserted-by":"publisher","first-page":"100319","DOI":"10.1016\/j.esmoop.2021.100319","volume":"6","author":"N Coleman","year":"2021","unstructured":"Coleman, N. et al. Beyond epidermal growth factor receptor: MET amplification as a general resistance driver to targeted therapy in oncogene-driven non-small-cell lung cancer. ESMO Open 6, 100319 (2021).","journal-title":"ESMO Open"},{"key":"2682_CR521","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.lungcan.2011.06.004","volume":"75","author":"A Tanaka","year":"2012","unstructured":"Tanaka, A. et al. Co-existence of positive MET FISH status with EGFR mutations signifies poor prognosis in lung adenocarcinoma patients. Lung Cancer 75, 89\u201394 (2012).","journal-title":"Lung Cancer"},{"key":"2682_CR522","doi-asserted-by":"publisher","first-page":"3048","DOI":"10.1158\/1078-0432.CCR-15-2061","volume":"22","author":"JH Tong","year":"2016","unstructured":"Tong, J. H. et al. MET amplification and exon 14 splice site mutation define unique molecular subgroups of non-small cell lung carcinoma with poor prognosis. Clin. Cancer Res. 22, 3048\u20133056 (2016).","journal-title":"Clin. Cancer Res."},{"key":"2682_CR523","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1200\/JCO.18.00177","volume":"37","author":"GGY Lai","year":"2019","unstructured":"Lai, G. G. Y. et al. Clonal MET amplification as a determinant of tyrosine kinase inhibitor resistance in epidermal growth factor receptor-mutant non-small-cell lung cancer. J. Clin. Oncol. 37, 876\u2013884 (2019).","journal-title":"J. Clin. Oncol."},{"key":"2682_CR524","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1200\/JCO.2008.19.1635","volume":"27","author":"F Cappuzzo","year":"2009","unstructured":"Cappuzzo, F. et al. Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. J. Clin. Oncol. 27, 1667\u20131674 (2009).","journal-title":"J. Clin. Oncol."},{"key":"2682_CR525","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1093\/annonc\/mdn635","volume":"20","author":"F Cappuzzo","year":"2009","unstructured":"Cappuzzo, F. et al. MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients. Ann. Oncol. 20, 298\u2013304 (2009).","journal-title":"Ann. Oncol."},{"key":"2682_CR526","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/j.jtho.2016.04.033","volume":"11","author":"SA Noonan","year":"2016","unstructured":"Noonan, S. A. et al. Identifying the appropriate FISH criteria for defining MET copy number-driven lung adenocarcinoma through oncogene overlap analysis. J. Thorac. Oncol. 11, 1293\u20131304 (2016).","journal-title":"J. Thorac. Oncol."},{"key":"2682_CR527","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1158\/2159-8290.CD-19-1446","volume":"10","author":"G Recondo","year":"2020","unstructured":"Recondo, G., Che, J., Janne, P. A. & Awad, M. M. Targeting MET dysregulation in cancer. Cancer Discov. 10, 922\u2013934 (2020).","journal-title":"Cancer Discov."},{"key":"2682_CR528","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jtho.2016.10.014","volume":"12","author":"A Drilon","year":"2017","unstructured":"Drilon, A., Cappuzzo, F., Ou, S. I. & Camidge, D. R. Targeting MET in lung cancer: will expectations finally be MET?. J. Thorac. Oncol. 12, 15\u201326 (2017).","journal-title":"J. Thorac. Oncol."},{"key":"2682_CR529","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1158\/2159-8290.CD-16-1337","volume":"7","author":"EJ Jordan","year":"2017","unstructured":"Jordan, E. J. et al. Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies. Cancer Discov. 7, 596\u2013609 (2017).","journal-title":"Cancer Discov."},{"key":"2682_CR530","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1038\/nm.3729","volume":"20","author":"Z Zheng","year":"2014","unstructured":"Zheng, Z. et al. Anchored multiplex PCR for targeted next-generation sequencing. Nat. Med. 20, 1479\u20131484 (2014).","journal-title":"Nat. Med."},{"key":"2682_CR531","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s40164-021-00245-y","volume":"10","author":"LX Peng","year":"2021","unstructured":"Peng, L. X. et al. MET amplification identified by next-generation sequencing and its clinical relevance for MET inhibitors. Exp. Hematol. Oncol. 10, 52 (2021).","journal-title":"Exp. Hematol. Oncol."},{"key":"2682_CR532","doi-asserted-by":"publisher","first-page":"3129","DOI":"10.1158\/1535-7163.MCT-08-0013","volume":"7","author":"SM Wilhelm","year":"2008","unstructured":"Wilhelm, S. M. et al. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol. Cancer Ther. 7, 3129\u20133140 (2008).","journal-title":"Mol. Cancer Ther."},{"key":"2682_CR533","doi-asserted-by":"publisher","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","volume":"64","author":"SM Wilhelm","year":"2004","unstructured":"Wilhelm, S. M. et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64, 7099\u20137109 (2004).","journal-title":"Cancer Res."},{"key":"2682_CR534","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.febslet.2013.12.025","volume":"588","author":"D Leiser","year":"2014","unstructured":"Leiser, D. et al. Targeting of the MET receptor tyrosine kinase by small molecule inhibitors leads to MET accumulation by impairing the receptor downregulation. FEBS Lett. 588, 653\u2013658 (2014).","journal-title":"FEBS Lett."},{"key":"2682_CR535","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.bbrc.2012.12.120","volume":"431","author":"M Humbert","year":"2013","unstructured":"Humbert, M. et al. Protective autophagy is involved in resistance towards MET inhibitors in human gastric adenocarcinoma cells. Biochem. Biophys. Res. Commun. 431, 264\u2013269 (2013).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2682_CR536","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s40487-016-0031-1","volume":"4","author":"W Hassan","year":"2016","unstructured":"Hassan, W., Chitcholtan, K., Sykes, P. & Garrill, A. A combination of two receptor tyrosine kinase inhibitors, canertinib and PHA665752 compromises ovarian cancer cell growth in 3D cell models. Oncol. Ther. 4, 257\u2013274 (2016).","journal-title":"Oncol. Ther."},{"key":"2682_CR537","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1158\/1535-7163.MCT-07-2045","volume":"7","author":"Y Yang","year":"2008","unstructured":"Yang, Y. et al. A selective small molecule inhibitor of c-Met, PHA-665752, reverses lung premalignancy induced by mutant K-ras. Mol. Cancer Ther. 7, 952\u2013960 (2008).","journal-title":"Mol. Cancer Ther."},{"key":"2682_CR538","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1002\/(SICI)1098-2264(199812)23:4<307::AID-GCC5>3.0.CO;2-#","volume":"23","author":"M Nessling","year":"1998","unstructured":"Nessling, M. et al. Mapping of chromosomal imbalances in gastric adenocarcinoma revealed amplified protooncogenes MYCN, MET, WNT2, and ERBB2. Genes Chromosomes Cancer 23, 307\u2013316 (1998).","journal-title":"Genes Chromosomes Cancer"},{"key":"2682_CR539","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1002\/(SICI)1098-2264(199904)24:4<299::AID-GCC2>3.0.CO;2-U","volume":"24","author":"C Sakakura","year":"1999","unstructured":"Sakakura, C. et al. Gains, losses, and amplifications of genomic materials in primary gastric cancers analyzed by comparative genomic hybridization. Genes Chromosomes Cancer 24, 299\u2013305 (1999).","journal-title":"Genes Chromosomes Cancer"},{"key":"2682_CR540","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/0006-291X(92)91548-5","volume":"189","author":"H Kuniyasu","year":"1992","unstructured":"Kuniyasu, H. et al. Frequent amplification of the c-met gene in scirrhous type stomach cancer. Biochem. Biophys. Res. Commun. 189, 227\u2013232 (1992).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2682_CR541","doi-asserted-by":"publisher","first-page":"175883592412345","DOI":"10.1177\/17588359241234504","volume":"16","author":"MM Fang","year":"2024","unstructured":"Fang, M. M. et al. Molecular features and clinical outcomes of EGFR-mutated, MET-amplified non-small-cell lung cancer after resistance to dual-targeted therapy. Ther. Adv. Med. Oncol. 16, 17588359241234504 (2024).","journal-title":"Ther. Adv. Med. Oncol."},{"key":"2682_CR542","doi-asserted-by":"publisher","first-page":"E1301","DOI":"10.1073\/pnas.1210353110","volume":"110","author":"JF Knight","year":"2013","unstructured":"Knight, J. F. et al. Met synergizes with p53 loss to induce mammary tumors that possess features of claudin-low breast cancer. Proc. Natl. Acad. Sci. USA 110, E1301\u2013E1310 (2013).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2682_CR543","doi-asserted-by":"publisher","first-page":"251","DOI":"10.4143\/crt.2012.44.4.251","volume":"44","author":"HY Jung","year":"2012","unstructured":"Jung, H. Y., Joo, H. J., Park, J. K. & Kim, Y. H. The blocking of c-met signaling induces apoptosis through the increase of p53 protein in lung cancer. Cancer Res. Treat. 44, 251\u2013261 (2012).","journal-title":"Cancer Res. Treat."},{"key":"2682_CR544","doi-asserted-by":"publisher","first-page":"3154","DOI":"10.1172\/JCI65566","volume":"123","author":"S Takeda","year":"2013","unstructured":"Takeda, S. et al. HGF-MET signals via the MLL-ETS2 complex in hepatocellular carcinoma. J. Clin. Invest. 123, 3154\u20133165 (2013).","journal-title":"J. Clin. Invest."},{"key":"2682_CR545","doi-asserted-by":"publisher","first-page":"20664","DOI":"10.1074\/jbc.M111.326058","volume":"287","author":"HC Lin","year":"2012","unstructured":"Lin, H. C. et al. Fas ligand enhances malignant behavior of tumor cells through interaction with Met, hepatocyte growth factor receptor, in lipid rafts. J. Biol. Chem. 287, 20664\u201320673 (2012).","journal-title":"J. Biol. Chem."},{"key":"2682_CR546","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1038\/sj.cdd.4402080","volume":"14","author":"B Foveau","year":"2007","unstructured":"Foveau, B. et al. Amplification of apoptosis through sequential caspase cleavage of the MET tyrosine kinase receptor. Cell Death Differ. 14, 752\u2013764 (2007).","journal-title":"Cell Death Differ."},{"key":"2682_CR547","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.lungcan.2015.10.020","volume":"90","author":"Y Togashi","year":"2015","unstructured":"Togashi, Y. et al. MET gene exon 14 deletion created using the CRISPR\/Cas9 system enhances cellular growth and sensitivity to a MET inhibitor. Lung Cancer 90, 590\u2013597 (2015).","journal-title":"Lung Cancer"},{"key":"2682_CR548","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.canlet.2014.10.034","volume":"356","author":"L Ding","year":"2015","unstructured":"Ding, L. et al. SAHA triggered MET activation contributes to SAHA tolerance in solid cancer cells. Cancer Lett. 356, 828\u2013836 (2015).","journal-title":"Cancer Lett."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02682-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02682-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02682-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T06:17:55Z","timestamp":1786429075000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02682-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,11]]},"references-count":548,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2682"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02682-9","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,11]]},"assertion":[{"value":"13 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"328"}}